{ "$schema_version": "5.3", "review_mode": "fresh", "claim_restatement": { "index_wording": "Once-weekly injectable semaglutide maintenance doses below 0.5 mg cause clinically meaningful sustained weight loss in adults with overweight or obesity.", "entry_form": "claim", "gradeable_restatement": "Once-weekly injectable semaglutide maintenance doses below 0.5 mg cause clinically meaningful sustained weight loss in adults meeting the registered BMI and comorbidity eligibility criteria.", "restatement_required": true, "split_into": [], "parent_claim": null, "scope_qualifiers": [ { "qualifier": "Baseline BMI, diabetes, age, comorbidity, route, exact weekly dose, maintenance duration, concurrent interventions and prespecified follow-up; no retrospective responder exclusions.", "determinable_before_outcome": true, "determined_from": "Enrollment and experimental design, before results; no responder-defined scope.", "action": "retained" } ], "original_claim": "Once-weekly injectable semaglutide maintenance doses below 0.5 mg cause clinically meaningful sustained weight loss in adults with overweight or obesity.", "restatement_note": "Grammatical clarification only: the original overweight/obesity wording retains the same preregistered BMI eligibility (BMI at least 30, or at least 27 with a weight-related condition), strictly below 0.5 mg weekly maintenance and 24-68 week endpoint. No daily-dose conversion, outcome-defined subgroup or eligibility change is introduced." }, "hypothesis": { "name": "Semaglutide Microdosing and Clinical Outcomes", "central_claim": "Once-weekly injectable semaglutide maintenance doses below 0.5 mg cause clinically meaningful sustained weight loss in adults meeting the registered BMI and comorbidity eligibility criteria.", "proposed_mechanism": "Once-weekly injectable semaglutide maintenance doses below 0.5 mg cause clinically meaningful sustained weight loss in adults with overweight or obesity.", "claimed_scope": "Once-weekly injectable semaglutide maintenance strictly below 0.5 mg beyond titration, in adults with baseline BMI at least 30 or at least 27 plus a weight-related condition, assessed for placebo-superior sustained weight loss at 24-68 weeks. Diabetes status is retained.", "claimed_level": [ "response", "maintenance" ], "is_conjunctive": false, "conjunctive_note": "The declared clinical causal proposition is represented by SC2. Target engagement, superiority, mechanism, generalization and benefit-harm companions are separately reported and do not substitute for this primary claim." }, "rubric_routing": { "primary_rubric": "06-metabolism-aging.md", "secondary_rubrics": [], "index_notes_applied": [ "The declared clinical causal proposition is represented by SC2. Target engagement, superiority, mechanism, generalization and benefit-harm companions are separately reported and do not substitute for this primary claim." ], "rubric_fit_note": "No shipped rubric directly covers obesity-drug efficacy or muscle preservation. Rubric 06 is the nearest metabolic route and is explicitly adapted: a randomized specified drug exposure changing prespecified weight responder/function outcomes is a clinical sufficiency perturbation. Lifespan is not imposed on this treatment claim. Original ladder, caps and verbatim rubric text remain unchanged. Dose/schedule, food-noise necessity and function are independently adjudicated." }, "subclaim_matrix": { "subclaims": [ { "id": "SC1", "statement": "Sub-0.5 mg once-weekly semaglutide maintenance engages appetite and metabolic pathways.", "subclaim_type": "mechanism", "scope": "Injectable semaglutide below 0.5 mg weekly; maintenance beyond titration; no daily-to-weekly dose conversion", "claimed_scope": "Injectable semaglutide below 0.5 mg weekly; maintenance beyond titration; no daily-to-weekly dose conversion", "governing_rubric": "06-metabolism-aging.md", "key_evidence_anchor": "Dose-ranging human pharmacodynamics", "hsef_level": "Γ", "confidence": "Moderate", "governing_cap_or_threshold": "Quoted boundary and upward audit below.", "rationale": "Weekly dose-finding included 0.1-0.8 mg without escalation over 12 weeks in diabetes, supporting exposure-response plausibility. Its examined abstract does not isolate low-arm appetite effects, and glycemic change alone is not a clinical phenotype crossing. The 1/2.4 mg and oral appetite experiments cannot establish sustained engagement of both registered pathways under the strict microdose maintenance exposure.", "rubric_adaptation": "Assess actual sub-0.5 mg weekly maintenance exposure and appetite/metabolic readouts; isolated glycemia or pharmacokinetics is a proxy and cannot establish complete functional engagement." }, { "id": "SC2", "statement": "Sub-0.5 mg once-weekly semaglutide maintenance produces at least 5 percent weight loss compared with placebo at 24-68 weeks.", "subclaim_type": "sufficiency", "scope": "Baseline BMI at least 30, or at least 27 with a weight-related condition; diabetes status retained; exact dose and horizon", "claimed_scope": "Baseline BMI at least 30, or at least 27 with a weight-related condition; diabetes status retained; exact dose and horizon", "governing_rubric": "06-metabolism-aging.md", "key_evidence_anchor": "Direct randomized low-dose maintenance trials", "hsef_level": "Γ", "confidence": "Moderate", "governing_cap_or_threshold": "Quoted boundary and upward audit below.", "rationale": "No examined randomized original assigns strictly below 0.5 mg weekly maintenance versus placebo for at least 5% loss at 24-68 weeks in the registered BMI-defined population. Twelve-week weekly dose-finding is too short; daily dose-ranging has another schedule; 0.5/1/2.4 mg trials have another maintenance exposure. Small mixed-dose and cointervention cohorts provide partial support without a clean exact-scope causal perturbation. This is an evidence gap, not proof that microdosing cannot work. The largest on-exposure record, a federated EHR cohort of 814 adults on sustained 0.25 mg-only prescriptions (PMID 42857675), observed -2.2% mean 12-month weight change; being observational, without placebo and prescription-selected, it leans against the claim without supplying the missing placebo-controlled test.", "rubric_adaptation": "Positive causal crossing requires the registered weekly maintenance dose, baseline eligibility, placebo contrast and at least 5% clinical weight loss over 24-68 weeks. Do not convert daily milligrams into weekly equivalence or extract initiation-titration response as long maintenance." }, { "id": "SC3", "statement": "Microdosing provides weight-loss and clinical benefits comparable to 2.4 mg weekly with fewer adverse effects.", "subclaim_type": "generalization", "scope": "Same eligibility and follow-up; direct comparison; benefits and harms measured together", "claimed_scope": "Same eligibility and follow-up; direct comparison; benefits and harms measured together", "governing_rubric": "06-metabolism-aging.md", "key_evidence_anchor": "Dose-comparison noninferiority and adverse-event trials", "hsef_level": "Α", "confidence": "Moderate", "governing_cap_or_threshold": "Quoted boundary and upward audit below.", "rationale": "Comparable weight and clinical benefits to 2.4 mg plus fewer adverse effects is not established by a direct randomized noninferiority/benefit-harm contrast. Final-dose observational nulls are not equivalence tests. A lower-dose tolerability hypothesis has biological rationale but the full positive equivalence conjunction remains speculative; exact-dose clinical data are missing.", "rubric_adaptation": "Direct matched noninferiority plus benefit-harm outcomes are required. Absence of a significant observational final-dose difference is not evidence of equivalence." }, { "id": "SC4", "statement": "Reduction in reported food noise is a necessary mediator of clinical weight loss.", "subclaim_type": "mechanism", "scope": "Semaglutide-exposed adults; validated construct distinct from appetite and intake", "claimed_scope": "Semaglutide-exposed adults; validated construct distinct from appetite and intake", "governing_rubric": "06-metabolism-aging.md", "key_evidence_anchor": "Mediator manipulation or dissociation", "hsef_level": "Γ", "confidence": "Moderate", "governing_cap_or_threshold": "Quoted boundary and upward audit below.", "rationale": "Randomized semaglutide experiments establish changes in intake, appetite and some reward measures; validated food-noise measurements in the examined semaglutide survey remain retrospective and descriptive. In a 60-week trial, measured intake differences persist at 20/40/60 weeks while hunger and food-preoccupation contrasts lose significance after week 20; food-reward responsiveness (Power of Food Scale), the measure closest to the food-noise construct, still differed at week 40, and only at week 60 did no subjective contrast remain. This narrows an obligatory subjective pathway but does not directly remove the validated construct. Necessary food-noise mediation remains partial-system plausibility, not a demonstrated dependency.", "rubric_adaptation": "Necessity requires a validated food-noise construct and a mediator perturbation or credible dissociation that establishes dependency. Appetite, nausea, craving, energy intake and FNQ are distinct measures." }, { "id": "SC5", "statement": "Low-dose semaglutide prevents clinically important muscle dysfunction during weight loss.", "subclaim_type": "generalization", "scope": "Strength and physical function measured; lean mass alone excluded", "claimed_scope": "Strength and physical function measured; lean mass alone excluded", "governing_rubric": "06-metabolism-aging.md", "key_evidence_anchor": "Direct dose comparisons with strength and function", "hsef_level": "Γ", "confidence": "Moderate", "governing_cap_or_threshold": "Quoted boundary and upward audit below.", "rationale": "Animal atrophy and co-treatment experiments plus mixed human functional observations support a possible muscle-related pathway. No direct human microdose comparison demonstrates prevention of clinically important strength or function loss. SEMALEAN grip improvement at 2.4 mg is uncontrolled; retrospective older-diabetes decline is confounded; MRI/DXA mass changes and relative lean proportion cannot substitute for function.", "rubric_adaptation": "Direct microdose-versus-standard-dose function/strength comparison is required; lean mass, relative lean fraction and heart-failure symptom scores do not establish muscle protection." } ], "aggregation_rule": "primary-subclaim", "aggregation_preregistered": true, "aggregation_rationale": "The declared clinical causal proposition is represented by SC2. Target engagement, superiority, mechanism, generalization and benefit-harm companions are separately reported and do not substitute for this primary claim.", "primary_subclaim_id": "SC2", "aggregation_derivation": "The preregistered primary-subclaim rule returns Γ from SC2. Fifty-nine relevant original reports were examined, but none directly supplies the registered below-0.5 mg weekly, 24-68-week placebo-controlled maintenance experiment. Standard-dose clinical success is preserved as a different proposition. Lower-dose anecdotes, daily dose-ranging and titration do not replace the missing exposure-specific test.", "aggregation_alternatives": { "weakest_link_would_return": "Α", "primary_subclaim_would_return": "Γ", "scope_matched_would_return": "Γ", "note": "Separate narrow successes do not replace the preregistered full-scope gate." }, "index_rule_deviation": "" }, "competing_models": { "models_evaluated": [ { "rank_in_tournament": 3, "model_id": "M1", "is_nominal": true, "name": "Microdose maintenance retains clinical efficacy", "core_claim": "The registered low weekly maintenance exposure has sufficient clinical action for sustained weight loss.", "explains_what_nominal_does_not": "The registered low weekly maintenance exposure has sufficient clinical action for sustained weight loss.", "strongest_supporting_evidence": [ "Short weekly dose-finding and small low/mixed-dose cohorts support plausibility." ], "strongest_contradictory_evidence": [ "No matched placebo-controlled 24-68-week exact-exposure original was examined." ], "hsef_level_for_this_model": "Γ", "rationale": "Short weekly dose-finding and small low/mixed-dose cohorts support plausibility. No matched placebo-controlled 24-68-week exact-exposure original was examined." }, { "rank_in_tournament": 1, "model_id": "M2", "is_nominal": false, "name": "Multiple appetite and energy-intake pathways support drug response", "core_claim": "Measured pharmacological exposure lowers intake through multiple central/peripheral pathways without requiring every subjective food-noise score to remain reduced.", "explains_what_nominal_does_not": "Measured pharmacological exposure lowers intake through multiple central/peripheral pathways without requiring every subjective food-noise score to remain reduced.", "strongest_supporting_evidence": [ "Randomized appetite/intake studies and STEP clinical trials show real drug benefit; the 60-week trial sustains intake differences after hunger and food-preoccupation contrasts fade, although food-reward responsiveness still differed at week 40." ], "strongest_contradictory_evidence": [ "The exact necessary human pathway is not isolated and standard-dose effects do not prove microdose efficacy." ], "hsef_level_for_this_model": "Ε", "rationale": "Randomized appetite/intake studies and STEP clinical trials show real drug benefit; the 60-week trial sustains intake differences after hunger and food-preoccupation contrasts fade, although food-reward responsiveness still differed at week 40. The exact necessary human pathway is not isolated and standard-dose effects do not prove microdose efficacy." }, { "rank_in_tournament": 2, "model_id": "M3", "is_nominal": false, "name": "Behavioral energy restriction and clinical support contribute to observed loss", "core_claim": "Calorie goals, counseling and other metabolic treatments produce weight loss alongside or independently of the alleged microdose mechanism.", "explains_what_nominal_does_not": "Calorie goals, counseling and other metabolic treatments produce weight loss alongside or independently of the alleged microdose mechanism.", "strongest_supporting_evidence": [ "STEP 3 placebo with intensive support loses weight; small PCOS cohorts add metformin; these are plausible cointervention contributions." ], "strongest_contradictory_evidence": [ "Placebo/support arms do not explain away randomized standard-dose drug advantages and cannot partition the entire uncontrolled microdose response." ], "hsef_level_for_this_model": "Δ", "rationale": "STEP 3 placebo with intensive support loses weight; small PCOS cohorts add metformin; these are plausible cointervention contributions. Placebo/support arms do not explain away randomized standard-dose drug advantages and cannot partition the entire uncontrolled microdose response." }, { "rank_in_tournament": 4, "model_id": "M4", "is_nominal": false, "name": "Persistence and response-selected dosing shape apparent low-dose success", "core_claim": "Clinicians maintain lower doses partly because of prior success, tolerability and cost, making final dose a consequence of earlier response.", "explains_what_nominal_does_not": "Clinicians maintain lower doses partly because of prior success, tolerability and cost, making final dose a consequence of earlier response.", "strongest_supporting_evidence": [ "FLEX-SEMA explicitly records satisfactory results as the principal maintenance reason; the reduced-frequency case series selects plateau achievers." ], "strongest_contradictory_evidence": [ "No randomized dose-assignment test quantifies how much selection explains the apparent effect." ], "hsef_level_for_this_model": "Β", "rationale": "FLEX-SEMA explicitly records satisfactory results as the principal maintenance reason; the reduced-frequency case series selects plateau achievers. No randomized dose-assignment test quantifies how much selection explains the apparent effect." } ], "tournament_summary": "Descriptive comparison; does not modify the nominal score. The 60-week randomized original PMID 42323166 separates a sustained objective intake response from hunger and food-preoccupation contrasts that lose significance after week 20, although food-reward responsiveness still differed at week 40. STEP 3 PMID 33625476 then shows matched behavioral support alone contributes weight loss yet does not explain away the standard-dose drug contrast. Neither is an exact microdose test.", "study_separating_rank1_from_rank2": "The 60-week randomized original PMID 42323166 separates a sustained objective intake response from hunger and food-preoccupation contrasts that lose significance after week 20, although food-reward responsiveness still differed at week 40. STEP 3 PMID 33625476 then shows matched behavioral support alone contributes weight loss yet does not explain away the standard-dose drug contrast. Neither is an exact microdose test.", "nominal_wins_only_by_funding_artifact": false, "level_unchanged_by_tournament": true }, "evidence_inventory": [ { "n": 1, "pmid": "30122305", "title": "Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial.", "citation": "O'Neil PM, Birkenfeld AL, McGowan B et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet (London, England). 2018.", "doi": "10.1016/S0140-6736(18)31773-2", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/30122305/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/30122305/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID30122305", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "mixed", "what_it_shows": "Randomized 52-week obesity trial found 6.0%-13.8% loss with 0.05-0.4 mg DAILY semaglutide versus 2.3% placebo; gastrointestinal events were dose related.", "what_it_does_not_show": "Every active semaglutide dose was administered daily; the trial does not test sub-0.5 mg weekly maintenance or permit arithmetic conversion of exposures.", "confounders_present": [ "Every active semaglutide dose was administered daily; the trial does not test sub-0.5 mg weekly maintenance or permit arithmetic conversion of exposures." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "Pivotal test, including null or negative results and restricted contexts; this flag is not a positive threshold crossing.", "shared_components": [] }, { "n": 2, "pmid": "41725422", "title": "Flexible dose of semaglutide reduces early discontinuation while maintaining comparable outcomes in obese patients: FLEX-SEMA 2.4 mg, an Italian real-world study.", "citation": "Pampanelli S, Terzoni S, Pantanetti P et al. Flexible dose of semaglutide reduces early discontinuation while maintaining comparable outcomes in obese patients: FLEX-SEMA 2.4 mg, an Italian real-world study. Diabetes, obesity & metabolism. 2026.", "doi": "10.1111/dom.70538", "pmcid": "PMC13071210", "url": "https://pubmed.ncbi.nlm.nih.gov/41725422/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/41725422/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID41725422", "access_depth": "full_text_partial", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:MATERIALS AND METHODS:paragraph0, 1:MATERIALS AND METHODS:paragraph1, 1:MATERIALS AND METHODS:paragraph7, 1:MATERIALS AND METHODS:paragraph8, 2:RESULTS:paragraph1, 2:RESULTS:paragraph3, 2:RESULTS:paragraph14, 2:RESULTS:paragraph15, 2:RESULTS:paragraph16, 2:RESULTS:paragraph19. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "human observational", "decisive_perturbation": true, "endogenous": false, "direction": "mixed", "what_it_shows": "FLEX-SEMA documented response-selected flexible dosing; 5.4% remained on 0.25 mg at three months, and the original body distinguishes cumulative six-month responders from weight-loss bins. The same source reports adverse events in 56.8% of patients at three months and 32.6% at six months, early discontinuation rising from 6.3% to 10.5%, and dose maintenance attributed to satisfactory results (40%), cost (30%) and adverse events (27.5%).", "what_it_does_not_show": "No exact long-term below-0.5 mg placebo contrast; satisfactory prior response drives dose maintenance. Indexed abstract mislabels bin percentages as cumulative thresholds, so original body governs.", "confounders_present": [ "No exact long-term below-0.5 mg placebo contrast; satisfactory prior response drives dose maintenance. Indexed abstract mislabels bin percentages as cumulative thresholds, so original body governs." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "Pivotal test, including null or negative results and restricted contexts; this flag is not a positive threshold crossing.", "shared_components": [] }, { "n": 3, "pmid": "28266779", "title": "Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity.", "citation": "Blundell J, Finlayson G, Axelsen M et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes, obesity & metabolism. 2017.", "doi": "10.1111/dom.12932", "pmcid": "PMC5573908", "url": "https://pubmed.ncbi.nlm.nih.gov/28266779/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/28266779/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID28266779", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC4" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "Thirty-person randomized crossover at 12 weeks and 1 mg weekly reduced daily ad-libitum intake 24% and body weight 5 kg with altered appetite and food cravings.", "what_it_does_not_show": "Dose escalated to 1 mg; early 0.25 mg titration is not isolated; eating-control measures are not necessary food-noise mediator perturbations.", "confounders_present": [ "Dose escalated to 1 mg; early 0.25 mg titration is not isolated; eating-control measures are not necessary food-noise mediator perturbations." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 4, "pmid": "36857477", "title": "Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes.", "citation": "Heise T, DeVries JH, Urva S et al. Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes. Diabetes care. 2023.", "doi": "10.2337/dc22-1710", "pmcid": "PMC10154650", "url": "https://pubmed.ncbi.nlm.nih.gov/36857477/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/36857477/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID36857477", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3", "SC4", "SC5" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "Secondary randomized tirzepatide 15 mg versus semaglutide 1 mg versus placebo analysis found greater weight/fat loss with tirzepatide despite similar measured appetite and meal-intake changes between drugs.", "what_it_does_not_show": "One meal/intake instrument does not isolate full energy balance or validated food-noise necessity; no microdose or muscle-function prevention tested.", "confounders_present": [ "One meal/intake instrument does not isolate full energy balance or validated food-noise necessity; no microdose or muscle-function prevention tested." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 5, "pmid": "33269530", "title": "The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity.", "citation": "Friedrichsen M, Breitschaft A, Tadayon S et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes, obesity & metabolism. 2021.", "doi": "10.1111/dom.14280", "pmcid": "PMC7898914", "url": "https://pubmed.ncbi.nlm.nih.gov/33269530/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/33269530/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID33269530", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC4" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "Seventy-two-person randomized 20-week trial of 2.4 mg weekly reduced intake 35%, weight 9.9% and hunger/cravings versus placebo; no late gastric-emptying delay by indirect test.", "what_it_does_not_show": "No sub-0.5 mg maintenance or specific food-noise mediator manipulation; paracetamol absorption is an indirect gastric-emptying instrument.", "confounders_present": [ "No sub-0.5 mg maintenance or specific food-noise mediator manipulation; paracetamol absorption is an indirect gastric-emptying instrument." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 6, "pmid": "39082206", "title": "Effect of oral semaglutide on energy intake, appetite, control of eating and gastric emptying in adults living with obesity: A randomized controlled trial.", "citation": "Gabe MBN, Breitschaft A, Knop FK et al. Effect of oral semaglutide on energy intake, appetite, control of eating and gastric emptying in adults living with obesity: A randomized controlled trial. Diabetes, obesity & metabolism. 2024.", "doi": "10.1111/dom.15802", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/39082206/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/39082206/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID39082206", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC4" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "Randomized 61-person 20-week oral 50 mg trial reduced energy intake and appetite with 9.8% weight loss versus 1.5% placebo.", "what_it_does_not_show": "Oral daily bioavailability and exposure differ from weekly injectable microdoses; appetite changes do not prove necessary food-noise mediation.", "confounders_present": [ "Oral daily bioavailability and exposure differ from weekly injectable microdoses; appetite changes do not prove necessary food-noise mediation." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 7, "pmid": "33184979", "title": "Effects of oral semaglutide on energy intake, food preference, appetite, control of eating and body weight in subjects with type 2 diabetes.", "citation": "Gibbons C, Blundell J, Tetens Hoff S et al. Effects of oral semaglutide on energy intake, food preference, appetite, control of eating and body weight in subjects with type 2 diabetes. Diabetes, obesity & metabolism. 2021.", "doi": "10.1111/dom.14255", "pmcid": "PMC7839771", "url": "https://pubmed.ncbi.nlm.nih.gov/33184979/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/33184979/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID33184979", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC4" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "Small crossover oral 14 mg daily trial in T2D reduced evaluated daily intake 38.9% and weight 2.7 kg versus 0.1 kg placebo with mixed meal-context appetite responses.", "what_it_does_not_show": "Thirteen evaluable subjects and oral formulation cannot establish weekly microdose maintenance; no mediator ablation.", "confounders_present": [ "Thirteen evaluable subjects and oral formulation cannot establish weekly microdose maintenance; no mediator ablation." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 8, "pmid": "42323166", "title": "Short- and long-term effects of semaglutide 2.4 mg on energy intake, appetite, and food reward: a 60-week, double-blind randomized controlled trial.", "citation": "Tronieri JS, Allison KC, DeRouen K et al. Short- and long-term effects of semaglutide 2.4 mg on energy intake, appetite, and food reward: a 60-week, double-blind randomized controlled trial. The American journal of clinical nutrition. 2026.", "doi": "10.1016/j.ajcnut.2026.101403", "pmcid": "PMC13494093", "url": "https://pubmed.ncbi.nlm.nih.gov/42323166/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/42323166/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "NCT05548647", "access_depth": "full_text_partial", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Methods:paragraph0, 1:Methods:paragraph1, 1:Methods:paragraph3, 1:Methods:paragraph4, 1:Methods:paragraph8, 1:Methods:paragraph12, 2:Results:paragraph8, 2:Results:paragraph10, 2:Results:paragraph19, 2:Results:paragraph21, 2:Results:paragraph22. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC4" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "mixed", "what_it_shows": "Randomized 120-person 60-week 2.4 mg trial sustained lower lunch intake at 20/40/60 weeks while hunger and food-preoccupation contrasts lost significance after week 20; food-reward responsiveness (Power of Food Scale), the measure closest to the food-noise construct, still differed at week 40, and only at week 60 did no subjective contrast remain.", "what_it_does_not_show": "Subjective appetite and food-preoccupation dissociation narrows simple mediation, but does not directly remove validated food noise or test microdoses.", "confounders_present": [ "Subjective appetite and food-preoccupation dissociation narrows simple mediation, but does not directly remove validated food noise or test microdoses." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "Pivotal test, including null or negative results and restricted contexts; this flag is not a positive threshold crossing.", "shared_components": [] }, { "n": 9, "pmid": "33567185", "title": "Once-Weekly Semaglutide in Adults with Overweight or Obesity.", "citation": "Wilding JPH, Batterham RL, Calanna S et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England journal of medicine. 2021.", "doi": "10.1056/NEJMoa2032183", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/33567185/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/33567185/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "STEP1-NCT03548935", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3", "SC5" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "STEP 1 randomized 1961 eligible non-diabetic adults to 2.4 mg weekly; 68-week mean weight loss 14.9% versus 2.4% placebo and 5% responders 86.4% versus 31.5%.", "what_it_does_not_show": "Drug efficacy at 2.4 mg with lifestyle support does not cross sub-0.5 mg maintenance threshold; participant-reported function does not isolate muscle preservation.", "confounders_present": [ "Drug efficacy at 2.4 mg with lifestyle support does not cross sub-0.5 mg maintenance threshold; participant-reported function does not isolate muscle preservation." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 10, "pmid": "35131037", "title": "Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial.", "citation": "Kadowaki T, Isendahl J, Khalid U et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. The lancet. Diabetes & endocrinology. 2022.", "doi": "10.1016/S2213-8587(22)00008-0", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/35131037/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/35131037/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID35131037", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3", "SC5" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "STEP 6 compared 2.4/1.7 mg weekly with placebo in 401 East Asian adults; 68-week mean losses 13.2/9.6% versus 2.1%, mapping a dose/context boundary.", "what_it_does_not_show": "Both doses greatly exceed microdose definition; visceral-fat imaging does not establish muscle function or microdose equivalence.", "confounders_present": [ "Both doses greatly exceed microdose definition; visceral-fat imaging does not establish muscle function or microdose equivalence." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 11, "pmid": "42764399", "title": "Effect of Semaglutide on Thigh Skeletal Muscle Volume, Fat Infiltration and Physical Function in People With Obesity: Secondary Analysis of STEP UP.", "citation": "Hjelmesæth J, Bhat S, Garvey WT et al. Effect of Semaglutide on Thigh Skeletal Muscle Volume, Fat Infiltration and Physical Function in People With Obesity: Secondary Analysis of STEP UP. Diabetes, obesity & metabolism. 2026.", "doi": "10.1111/dom.71323", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/42764399/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/42764399/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "STEPUP-NCT05646706", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC5" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "STEP UP MRI subset pooled 49 semaglutide 7.2/2.4 mg versus 6 placebo showed less fat infiltration and preserved sit-to-stand repetitions despite volume loss.", "what_it_does_not_show": "Tiny imbalanced subset with same 13-to-15 chair stands in both groups gives no positive microdose muscle-function prevention result; 72 weeks lies beyond registered weight horizon.", "confounders_present": [ "Tiny imbalanced subset with same 13-to-15 chair stands in both groups gives no positive microdose muscle-function prevention result; 72 weeks lies beyond registered weight horizon." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 12, "pmid": "29397376", "title": "Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.", "citation": "Pratley RE, Aroda VR, Lingvay I et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. The lancet. Diabetes & endocrinology. 2018.", "doi": "10.1016/S2213-8587(18)30024-X", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/29397376/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/29397376/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID29397376", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "SUSTAIN 7 randomized 1201 T2D patients; 0.5/1 mg weekly reduced weight 4.6/6.5 kg versus 2.3/3 kg dulaglutide at 40 weeks.", "what_it_does_not_show": "0.5 mg is explicitly excluded by strict below 0.5 mg registration; no placebo or matched 2.4 mg microdose-equivalence comparison.", "confounders_present": [ "0.5 mg is explicitly excluded by strict below 0.5 mg registration; no placebo or matched 2.4 mg microdose-equivalence comparison." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 13, "pmid": "40961953", "title": "Once-weekly semaglutide 7·2 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trial.", "citation": "Lingvay I, Bergenheim SJ, Buse JB et al. Once-weekly semaglutide 7·2 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trial. The lancet. Diabetes & endocrinology. 2025.", "doi": "10.1016/S2213-8587(25)00225-6", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/40961953/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/40961953/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "ErratumIn: PMID41932351" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID40961953", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3", "SC5" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "STEP UP T2D randomized 512 adults to 7.2/2.4 mg or placebo; 7.2 mg produced 13.2% versus 3.9% loss with dose-related dysaesthesia imbalance.", "what_it_does_not_show": "No sub-0.5 mg maintenance; 72-week horizon and parent-linked correction 41932351 must remain explicit; no muscle prevention outcome here.", "confounders_present": [ "No sub-0.5 mg maintenance; 72-week horizon and parent-linked correction 41932351 must remain explicit; no muscle prevention outcome here." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 14, "pmid": "39848268", "title": "Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA1c levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial.", "citation": "Davies MJ, van der Meer P, Verma S et al. Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA1c levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial. The lancet. Diabetes & endocrinology. 2025.", "doi": "10.1016/S2213-8587(24)00304-8", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/39848268/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/39848268/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "STEP-HFpEF-DM-NCT04916470", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC5" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "STEP-HFpEF DM secondary analysis found 2.4 mg weekly improved symptom/physical-limitations scores and weight across baseline HbA1c strata in 616 adults.", "what_it_does_not_show": "Heart-failure function is not dose-specific muscle-strength preservation; subgroup report shares parent trial and does not test microdose maintenance.", "confounders_present": [ "Heart-failure function is not dose-specific muscle-strength preservation; subgroup report shares parent trial and does not test microdose maintenance." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 15, "pmid": "41879791", "title": "Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes: A Post Hoc Secondary Analysis of the SOUL Randomized Clinical Trial.", "citation": "Mulvagh SL, Inzucchi SE, Marx N et al. Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes: A Post Hoc Secondary Analysis of the SOUL Randomized Clinical Trial. JAMA cardiology. 2026.", "doi": "10.1001/jamacardio.2026.0245", "pmcid": "PMC13019341", "url": "https://pubmed.ncbi.nlm.nih.gov/41879791/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/41879791/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID41879791", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "SOUL posthoc secondary analysis of 9650 randomized high-risk T2D adults found oral 14 mg exposure improved multiple risk factors and weight beyond placebo over 156 weeks.", "what_it_does_not_show": "Oral exposure, long horizon and surrogate contrasts do not establish weekly microdose benefits or comparable clinical benefit-harm profile.", "confounders_present": [ "Oral exposure, long horizon and surrogate contrasts do not establish weekly microdose benefits or comparable clinical benefit-harm profile." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 16, "pmid": "38826889", "title": "A Real-World Study of the Effectiveness and Safety of Semaglutide for Weight Loss.", "citation": "Tzoulis P, Batavanis M, Baldeweg S. A Real-World Study of the Effectiveness and Safety of Semaglutide for Weight Loss. Cureus. 2024.", "doi": "10.7759/cureus.59558", "pmcid": "PMC11144277", "url": "https://pubmed.ncbi.nlm.nih.gov/38826889/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/38826889/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID38826889", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "mixed", "what_it_shows": "Forty-person retrospective obesity series found observed loss at 3 months and in 25 six-month completers; maintenance was 1 mg in 16 and 2 mg in 9.", "what_it_does_not_show": "Lower-than-obesity-dose is not below 0.5 mg; uncontrolled attrition/completion and dose selection preclude microdose causality or noninferiority.", "confounders_present": [ "Lower-than-obesity-dose is not below 0.5 mg; uncontrolled attrition/completion and dose selection preclude microdose causality or noninferiority." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 17, "pmid": "42247231", "title": "Patient Experiences With GLP-1 Receptor Agonists.", "citation": "de Vere Hunt I, Ramirez-Posada M, Babu CS et al. Patient Experiences With GLP-1 Receptor Agonists. JAMA network open. 2026.", "doi": "10.1001/jamanetworkopen.2026.16951", "pmcid": "PMC13241945", "url": "https://pubmed.ncbi.nlm.nih.gov/42247231/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/42247231/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID42247231", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC4" ], "favors_models": [], "evidence_class": "Weak", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Qualitative interviews with 30 current/former GLP1 users describe reduced food noise, adverse effects, cost barriers and lifestyle facilitation.", "what_it_does_not_show": "Recruited testimonials without randomized mediator contrast cannot demonstrate necessary food-noise mechanism or exact-dose efficacy.", "confounders_present": [ "Recruited testimonials without randomized mediator contrast cannot demonstrate necessary food-noise mechanism or exact-dose efficacy." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 18, "pmid": "40259493", "title": "GLP-1 medication and weight loss: Barriers and motivators among 1659 participants managed in a virtual setting.", "citation": "Naveed M, Perez C, Ahmad E et al. GLP-1 medication and weight loss: Barriers and motivators among 1659 participants managed in a virtual setting. Diabetes, obesity & metabolism. 2025.", "doi": "10.1111/dom.16405", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/40259493/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/40259493/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID40259493", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC4" ], "favors_models": [], "evidence_class": "Weak", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Surveys/video diaries among 1659 virtual-care participants describe reduced food thoughts and satiety alongside cost, stigma and side-effect discontinuation.", "what_it_does_not_show": "Mixed drugs and self-report with selection do not isolate semaglutide microdose effects or causal necessity of food-noise reduction.", "confounders_present": [ "Mixed drugs and self-report with selection do not isolate semaglutide microdose effects or causal necessity of food-noise reduction." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 19, "pmid": "42217114", "title": "Retrospective Assessment of Food Noise Changes After Initiation of Injectable Semaglutide for Weight Management in the USA: The INFORM Survey.", "citation": "Arnaut T, Duncan S, Faurby M et al. Retrospective Assessment of Food Noise Changes After Initiation of Injectable Semaglutide for Weight Management in the USA: The INFORM Survey. Advances in therapy. 2026.", "doi": "10.1007/s12325-026-03636-x", "pmcid": "PMC13415491", "url": "https://pubmed.ncbi.nlm.nih.gov/42217114/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/42217114/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID42217114", "access_depth": "full_text_partial", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 2:Methods:paragraph1, 2:Methods:paragraph3, 2:Methods:paragraph4, 2:Methods:paragraph5, 2:Methods:paragraph11, 2:Methods:paragraph13, 3:Results:paragraph0, 3:Results:paragraph1, 3:Results:paragraph4. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC4" ], "favors_models": [], "evidence_class": "Moderate", "system": "human observational", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "INFORM reported lower remembered-to-current FNQ scores in 550 semaglutide users; original Methods/Results confirm 547 complete FNQ responses and descriptive analysis without statistical tests.", "what_it_does_not_show": "Recall, panel selection and mixed doses including 2.4 mg do not establish necessary mediation or exact microdose efficacy.", "confounders_present": [ "Recall, panel selection and mixed doses including 2.4 mg do not establish necessary mediation or exact microdose efficacy." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "Pivotal test, including null or negative results and restricted contexts; this flag is not a positive threshold crossing.", "shared_components": [] }, { "n": 20, "pmid": "42641845", "title": "The effects of glucagon-like peptide-1 receptor agonists on chemosensory function and ingestive behavior.", "citation": "Rutigliani G, Mattes RD. The effects of glucagon-like peptide-1 receptor agonists on chemosensory function and ingestive behavior. Physiology & behavior. 2026.", "doi": "10.1016/j.physbeh.2026.115486", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/42641845/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/42641845/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID42641845", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC4", "SC5" ], "favors_models": [], "evidence_class": "Moderate", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Cross-sectional 79-person GLP1RA study associated 6-month use with lower FNQ, food reward and intake; protein intake did not differ significantly.", "what_it_does_not_show": "Separate exposure groups and mixedagents/doses do not establish longitudinal mediation or muscle-strength preservation.", "confounders_present": [ "Separate exposure groups and mixedagents/doses do not establish longitudinal mediation or muscle-strength preservation." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 21, "pmid": "42049707", "title": "\"And just like that, quiet\": a content analysis of TikTok videos on food noise.", "citation": "Hayashi D, Kort J, Robles-Martinez IM et al. \"And just like that, quiet\": a content analysis of TikTok videos on food noise. Nutrition & diabetes. 2026.", "doi": "10.1038/s41387-026-00423-z", "pmcid": "PMC13265739", "url": "https://pubmed.ncbi.nlm.nih.gov/42049707/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/42049707/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID42049707", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC4" ], "favors_models": [], "evidence_class": "Weak", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "mixed", "what_it_shows": "Original 99-video TikTok analysis found food-noise content dominated by patient testimony and usually positive medication portrayals.", "what_it_does_not_show": "Engagement and reported experience describe promotion, not causal clinical efficacy; no field-wide HSEF belief survey or microdose comparison.", "confounders_present": [ "Engagement and reported experience describe promotion, not causal clinical efficacy; no field-wide HSEF belief survey or microdose comparison." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 22, "pmid": "26358288", "title": "A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes.", "citation": "Nauck MA, Petrie JR, Sesti G et al. A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes. Diabetes care. 2016.", "doi": "10.2337/dc15-0165", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/26358288/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/26358288/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "WEEKLY-SEMA-PHASE2-12W", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "mixed", "what_it_shows": "The 415-person randomized 12-week phase 2 study tested weekly 0.1-0.8 mg without escalation and higher escalated doses; glycemic and weight responses were dose dependent.", "what_it_does_not_show": "The abstract reports the largest weight effect at 1.6 mg without low-arm estimates; neither duration nor eligibility establishes the registered 24-68-week clinical claim.", "confounders_present": [ "The abstract reports the largest weight effect at 1.6 mg without low-arm estimates; neither duration nor eligibility establishes the registered 24-68-week clinical claim." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "Pivotal test, including null or negative results and restricted contexts; this flag is not a positive threshold crossing.", "shared_components": [] }, { "n": 23, "pmid": "28110911", "title": "Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial.", "citation": "Sorli C, Harashima SI, Tsoukas GM et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. The lancet. Diabetes & endocrinology. 2017.", "doi": "10.1016/S2213-8587(17)30013-X", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/28110911/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/28110911/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID28110911", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "SUSTAIN 1 found 3.73/4.53 kg weight loss with weekly 0.5/1 mg versus 0.98 kg with placebo at 30 weeks.", "what_it_does_not_show": "Both doses lie outside the strict below-0.5 mg registration; the trial does not isolate microdose efficacy in the specified obesity population.", "confounders_present": [ "Both doses lie outside the strict below-0.5 mg registration; the trial does not isolate microdose efficacy in the specified obesity population." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 24, "pmid": "28385659", "title": "Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.", "citation": "Ahrén B, Masmiquel L, Kumar H et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. The lancet. Diabetes & endocrinology. 2017.", "doi": "10.1016/S2213-8587(17)30092-X", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/28385659/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/28385659/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID28385659", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "SUSTAIN 2 found 4.3/6.1 kg loss with weekly 0.5/1 mg versus 1.9 kg with sitagliptin at 56 weeks, with more adverse-event discontinuation.", "what_it_does_not_show": "Excluded doses and an active comparator cannot establish microdose noninferiority to 2.4 mg or fewer harms.", "confounders_present": [ "Excluded doses and an active comparator cannot establish microdose noninferiority to 2.4 mg or fewer harms." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 25, "pmid": "28344112", "title": "Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial.", "citation": "Aroda VR, Bain SC, Cariou B et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. The lancet. Diabetes & endocrinology. 2017.", "doi": "10.1016/S2213-8587(17)30085-2", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/28344112/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/28344112/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID28344112", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "SUSTAIN 4 found weight loss with weekly 0.5/1 mg versus weight gain with glargine at 30 weeks, with fewer hypoglycemic events.", "what_it_does_not_show": "The open-label comparison, background drugs and excluded doses provide no direct microdose maintenance evidence.", "confounders_present": [ "The open-label comparison, background drugs and excluded doses provide no direct microdose maintenance evidence." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 26, "pmid": "29688502", "title": "Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial.", "citation": "Rodbard HW, Lingvay I, Reed J et al. Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial. The Journal of clinical endocrinology and metabolism. 2018.", "doi": "10.1210/jc.2018-00070", "pmcid": "PMC5991220", "url": "https://pubmed.ncbi.nlm.nih.gov/29688502/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/29688502/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID29688502", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "SUSTAIN 5 found 3.7/6.4 kg loss with weekly 0.5/1 mg versus 1.4 kg with placebo in basal-insulin-treated diabetes.", "what_it_does_not_show": "No below-0.5 mg maintenance arm was randomized; diabetes and insulin context must remain explicit.", "confounders_present": [ "No below-0.5 mg maintenance arm was randomized; diabetes and insulin context must remain explicit." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 27, "pmid": "29246950", "title": "Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.", "citation": "Ahmann AJ, Capehorn M, Charpentier G et al. Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial. Diabetes care. 2018.", "doi": "10.2337/dc17-0417", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/29246950/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/29246950/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID29246950", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "SUSTAIN 3 found 5.6 kg loss with weekly 1 mg versus 1.9 kg with extended-release exenatide at 56 weeks, with more gastrointestinal events.", "what_it_does_not_show": "Open-label approved-dose comparison does not establish microdose efficacy or equivalence to 2.4 mg.", "confounders_present": [ "Open-label approved-dose comparison does not establish microdose efficacy or equivalence to 2.4 mg." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 28, "pmid": "30833170", "title": "Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial.", "citation": "Zinman B, Bhosekar V, Busch R et al. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial. The lancet. Diabetes & endocrinology. 2019.", "doi": "10.1016/S2213-8587(19)30066-X", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/30833170/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/30833170/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "ErratumIn: PMID30872122", "ErratumIn: PMID31272930", "ErratumIn: PMID31621596" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID30833170", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "SUSTAIN 9 found 1 mg weekly added to SGLT2 therapy reduced weight beyond placebo; 0.25 mg was used only during four-week titration.", "what_it_does_not_show": "Titration cannot be credited as maintenance; three parent-linked errata are recorded without inventing their unexamined contents.", "confounders_present": [ "Titration cannot be credited as maintenance; three parent-linked errata are recorded without inventing their unexamined contents." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 29, "pmid": "31539622", "title": "Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10).", "citation": "Capehorn MS, Catarig AM, Furberg JK et al. Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes & metabolism. 2020.", "doi": "10.1016/j.diabet.2019.101117", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/31539622/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/31539622/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID31539622", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "SUSTAIN 10 found 5.8 kg loss with weekly 1 mg versus 1.9 kg with daily liraglutide at 30 weeks, with more gastrointestinal discontinuation.", "what_it_does_not_show": "No microdose arm; malformed inequality glyphs in the indexed abstract are not reproduced as precise threshold claims.", "confounders_present": [ "No microdose arm; malformed inequality glyphs in the indexed abstract are not reproduced as precise threshold claims." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 30, "pmid": "34293304", "title": "Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial.", "citation": "Frías JP, Auerbach P, Bajaj HS et al. Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial. The lancet. Diabetes & endocrinology. 2021.", "doi": "10.1016/S2213-8587(21)00174-1", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/34293304/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/34293304/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID34293304", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "SUSTAIN FORTE found a 2-versus-1 mg weight advantage significant under the trial-product estimand but not under treatment policy at 40 weeks.", "what_it_does_not_show": "Both doses are excluded; estimand-dependent superiority cannot establish microdose noninferiority or lower harm.", "confounders_present": [ "Both doses are excluded; estimand-dependent superiority cannot establish microdose noninferiority or lower harm." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] }, { "n": 31, "pmid": "31897524", "title": "Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial.", "citation": "McCrimmon RJ, Catarig AM, Frias JP et al. Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial. Diabetologia. 2020.", "doi": "10.1007/s00125-019-05065-8", "pmcid": "PMC6997246", "url": "https://pubmed.ncbi.nlm.nih.gov/31897524/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/31897524/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "SUSTAIN8-NCT03136484", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC5" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "SUSTAIN 8 DXA results showed lean mass decreased despite increased lean proportion, with nonsignificant semaglutide-versus-canagliflozin differences.", "what_it_does_not_show": "Only 114 of 178 had end-treatment data; no placebo, strength or function measurement establishes muscle dysfunction or protection.", "confounders_present": [ "Only 114 of 178 had end-treatment data; no placebo, strength or function measurement establishes muscle dysfunction or protection." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 32, "pmid": "33755728", "title": "Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.", "citation": "Rubino D, Abrahamsson N, Davies M et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.", "doi": "10.1001/jama.2021.3224", "pmcid": "PMC7988425", "url": "https://pubmed.ncbi.nlm.nih.gov/33755728/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/33755728/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "STEP4-NCT03548987", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3", "SC5" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "mixed", "what_it_shows": "STEP 4 randomized 803 participants tolerating 2.4 mg after run-in; continuation caused further loss whereas withdrawal caused regain over 48 weeks.", "what_it_does_not_show": "Selection after tolerability and a 2.4 mg regimen do not establish below-0.5 mg microdose maintenance efficacy.", "confounders_present": [ "Selection after tolerability and a 2.4 mg regimen do not establish below-0.5 mg microdose maintenance efficacy." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "Pivotal test, including null or negative results and restricted contexts; this flag is not a positive threshold crossing.", "shared_components": [] }, { "n": 33, "pmid": "35441470", "title": "Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.", "citation": "Wilding JPH, Batterham RL, Davies M et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, obesity & metabolism. 2022.", "doi": "10.1111/dom.14725", "pmcid": "PMC9542252", "url": "https://pubmed.ncbi.nlm.nih.gov/35441470/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/35441470/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "STEP1-NCT03548935", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "The exploratory STEP 1 extension found regain of roughly two-thirds of prior weight loss after drug and lifestyle support stopped.", "what_it_does_not_show": "Selected completers, shared parent data and simultaneous withdrawal of lifestyle support limit independent inference; no microdose arm.", "confounders_present": [ "Selected completers, shared parent data and simultaneous withdrawal of lifestyle support limit independent inference; no microdose arm." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 34, "pmid": "33667417", "title": "Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.", "citation": "Davies M, Færch L, Jeppesen OK et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet (London, England). 2021.", "doi": "10.1016/S0140-6736(21)00213-0", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/33667417/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/33667417/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "STEP2-NCT03552757", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "mixed", "what_it_shows": "STEP 2 randomized adults with diabetes to 2.4 mg, 1 mg or placebo; 2.4 mg caused 9.6% versus 3.4% loss at 68 weeks.", "what_it_does_not_show": "The dose comparison does not contain a below-0.5 mg arm; positive higher-dose effects cannot cross its registered threshold.", "confounders_present": [ "The dose comparison does not contain a below-0.5 mg arm; positive higher-dose effects cannot cross its registered threshold." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "Pivotal test, including null or negative results and restricted contexts; this flag is not a positive threshold crossing.", "shared_components": [] }, { "n": 35, "pmid": "33625476", "title": "Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial.", "citation": "Wadden TA, Bailey TS, Billings LK et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021.", "doi": "10.1001/jama.2021.1831", "pmcid": "PMC7905697", "url": "https://pubmed.ncbi.nlm.nih.gov/33625476/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/33625476/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "STEP3-NCT03611582", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "STEP 3 found 16.0% versus 5.7% weight loss with 2.4 mg versus placebo alongside matched intensive behavioral support.", "what_it_does_not_show": "A matched diet and counseling bundle does not isolate titration-dose maintenance or justify a microdose claim.", "confounders_present": [ "A matched diet and counseling bundle does not isolate titration-dose maintenance or justify a microdose claim." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 36, "pmid": "35015037", "title": "Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.", "citation": "Rubino DM, Greenway FL, Khalid U et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022.", "doi": "10.1001/jama.2021.23619", "pmcid": "PMC8753508", "url": "https://pubmed.ncbi.nlm.nih.gov/35015037/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/35015037/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID35015037", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "STEP 8 found 15.8% loss with weekly 2.4 mg versus 6.4% with daily liraglutide at 68 weeks.", "what_it_does_not_show": "Active comparisons were open-label with different titration/tolerability options; no microdose noninferiority was tested.", "confounders_present": [ "Active comparisons were open-label with different titration/tolerability options; no microdose noninferiority was tested." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 37, "pmid": "36216945", "title": "Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial.", "citation": "Garvey WT, Batterham RL, Bhatta M et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature medicine. 2022.", "doi": "10.1038/s41591-022-02026-4", "pmcid": "PMC9556320", "url": "https://pubmed.ncbi.nlm.nih.gov/36216945/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/36216945/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "STEP5-NCT03693430", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "STEP 5 found sustained 15.2% versus 2.6% loss with weekly 2.4 mg versus placebo at 104 weeks.", "what_it_does_not_show": "The high dose and longer horizon provide genuine comparator efficacy but not the registered microdose result.", "confounders_present": [ "The high dose and longer horizon provide genuine comparator efficacy but not the registered microdose result." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 38, "pmid": "36655300", "title": "Two-year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5.", "citation": "Wharton S, Batterham RL, Bhatta M et al. Two-year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5. Obesity (Silver Spring, Md.). 2023.", "doi": "10.1002/oby.23673", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/36655300/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/36655300/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "STEP5-NCT03693430", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC4" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "The STEP 5 eating-control subset showed sustained improvements in some craving domains correlated with weight loss; hunger/fullness effects were early.", "what_it_does_not_show": "Subset selection, multiplicity and correlation cannot show necessary mediation by a validated food-noise construct; this shares STEP 5 participants.", "confounders_present": [ "Subset selection, multiplicity and correlation cannot show necessary mediation by a validated food-noise construct; this shares STEP 5 participants." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 39, "pmid": "37952131", "title": "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.", "citation": "Lincoff AM, Brown-Frandsen K, Colhoun HM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. The New England journal of medicine. 2023.", "doi": "10.1056/NEJMoa2307563", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/37952131/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/37952131/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "SELECT-NCT03574597", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "SELECT found fewer major cardiovascular events with 2.4 mg than placebo in 17,604 adults with cardiovascular disease and no diabetes, with more discontinuation.", "what_it_does_not_show": "Hard clinical benefit at the tested dose does not establish comparable microdose benefit-harm or dose-specific noninferiority.", "confounders_present": [ "Hard clinical benefit at the tested dose does not establish comparable microdose benefit-harm or dose-specific noninferiority." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 40, "pmid": "38740993", "title": "Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial.", "citation": "Ryan DH, Lingvay I, Deanfield J et al. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nature medicine. 2024.", "doi": "10.1038/s41591-024-02996-7", "pmcid": "PMC11271387", "url": "https://pubmed.ncbi.nlm.nih.gov/38740993/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/38740993/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "SELECT-NCT03574597", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "SELECT anthropometric analysis found sustained 10.2% versus 1.5% weight loss at 208 weeks across baseline BMI strata.", "what_it_does_not_show": "Shared SELECT participants and flexible dose histories do not supply randomized below-0.5 mg maintenance evidence.", "confounders_present": [ "Shared SELECT participants and flexible dose histories do not supply randomized below-0.5 mg maintenance evidence." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 41, "pmid": "39948761", "title": "Safety profile of semaglutide versus placebo in the SELECT study: a randomized controlled trial.", "citation": "Kushner RF, Ryan DH, Deanfield J et al. Safety profile of semaglutide versus placebo in the SELECT study: a randomized controlled trial. Obesity (Silver Spring, Md.). 2025.", "doi": "10.1002/oby.24222", "pmcid": "PMC11897845", "url": "https://pubmed.ncbi.nlm.nih.gov/39948761/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/39948761/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "SELECT-NCT03574597", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "SELECT safety analysis found fewer serious events but more gastrointestinal discontinuation and gallbladder disorders with semaglutide.", "what_it_does_not_show": "Endpoint-specific benefit-harm and shared trial data cannot demonstrate a microdose safety advantage.", "confounders_present": [ "Endpoint-specific benefit-harm and shared trial data cannot demonstrate a microdose safety advantage." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 42, "pmid": "27633186", "title": "Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.", "citation": "Marso SP, Bain SC, Consoli A et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. The New England journal of medicine. 2016.", "doi": "10.1056/NEJMoa1607141", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/27633186/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/27633186/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "SUSTAIN6-NCT01720446", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "SUSTAIN 6 found fewer pooled major cardiovascular events but more retinopathy complications with weekly 0.5/1 mg in high-risk diabetes.", "what_it_does_not_show": "Both doses are excluded; pooled dose effects and noninferiority design cannot establish microdose hard outcomes or a uniformly safer profile.", "confounders_present": [ "Both doses are excluded; pooled dose effects and noninferiority design cannot establish microdose hard outcomes or a uniformly safer profile." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 43, "pmid": "38785209", "title": "Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.", "citation": "Perkovic V, Tuttle KR, Rossing P et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. The New England journal of medicine. 2024.", "doi": "10.1056/NEJMoa2403347", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/38785209/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/38785209/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "FLOW-NCT03819153", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "FLOW found fewer major kidney-composite events with weekly 1 mg versus placebo over 3.4 years in diabetes and kidney disease.", "what_it_does_not_show": "The dose, kidney-defined population and long horizon are specific; genuine benefit cannot be inherited by microdose claims.", "confounders_present": [ "The dose, kidney-defined population and long horizon are specific; genuine benefit cannot be inherited by microdose claims." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 44, "pmid": "37622681", "title": "Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.", "citation": "Kosiborod MN, Abildstrøm SZ, Borlaug BA et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. The New England journal of medicine. 2023.", "doi": "10.1056/NEJMoa2306963", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/37622681/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/37622681/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "STEP-HFpEF-NCT04788511", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC5" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "STEP-HFpEF found 2.4 mg improved six-minute walking and symptom/physical-limitations scores beyond placebo in obesity-related heart failure.", "what_it_does_not_show": "Exercise improvement is real but does not isolate muscle preservation or test low-dose dysfunction prevention.", "confounders_present": [ "Exercise improvement is real but does not isolate muscle preservation or test low-dose dysfunction prevention." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 45, "pmid": "38587233", "title": "Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes.", "citation": "Kosiborod MN, Petrie MC, Borlaug BA et al. Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes. The New England journal of medicine. 2024.", "doi": "10.1056/NEJMoa2313917", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/38587233/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/38587233/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "STEP-HFpEF-DM-NCT04916470", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC5" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "STEP-HFpEF DM found 2.4 mg improved walking and symptom/physical-limitations scores in obesity-related heart failure and diabetes.", "what_it_does_not_show": "Cardiorespiratory function is not isolated muscle strength; later analyses share this parent trial and contain no microdose arm.", "confounders_present": [ "Cardiorespiratory function is not isolated muscle strength; later analyses share this parent trial and contain no microdose arm." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 46, "pmid": "39476339", "title": "Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis.", "citation": "Bliddal H, Bays H, Czernichow S et al. Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis. The New England journal of medicine. 2024.", "doi": "10.1056/NEJMoa2403664", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/39476339/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/39476339/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID39476339", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC5" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "STEP 9 found 2.4 mg improved weight, knee pain and reported physical function more than placebo at 68 weeks.", "what_it_does_not_show": "Osteoarthritis symptom relief is not proof of microdose muscle preservation or prevention of sarcopenia.", "confounders_present": [ "Osteoarthritis symptom relief is not proof of microdose muscle preservation or prevention of sarcopenia." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 47, "pmid": "39089293", "title": "Efficacy and safety of once-weekly semaglutide 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial.", "citation": "McGowan BM, Bruun JM, Capehorn M et al. Efficacy and safety of once-weekly semaglutide 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial. The lancet. Diabetes & endocrinology. 2024.", "doi": "10.1016/S2213-8587(24)00182-7", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/39089293/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/39089293/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID39089293", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "STEP 10 found 13.9% versus 2.7% weight loss with 2.4 mg versus placebo at 52 weeks in obesity and prediabetes.", "what_it_does_not_show": "Clinical efficacy belongs to the tested standard-dose context; normoglycemia is not proof of comparable microdose hard outcomes.", "confounders_present": [ "Clinical efficacy belongs to the tested standard-dose context; normoglycemia is not proof of comparable microdose hard outcomes." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 48, "pmid": "38330988", "title": "Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial.", "citation": "Mu Y, Bao X, Eliaschewitz FG et al. Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial. The lancet. Diabetes & endocrinology. 2024.", "doi": "10.1016/S2213-8587(23)00388-1", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/38330988/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/38330988/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID38330988", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "STEP 7 found 12.1% versus 3.6% loss with 2.4 mg versus placebo in predominantly East Asian adults at 44 weeks.", "what_it_does_not_show": "Population replication of one pharmacological modality does not create direct microdose evidence or an independent causal line.", "confounders_present": [ "Population replication of one pharmacological modality does not create direct microdose evidence or an independent causal line." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 49, "pmid": "40825340", "title": "Once-weekly semaglutide 2·4 mg in an Asian population with obesity, defined as BMI ≥25 kg/m2, in South Korea and Thailand (STEP 11): a randomised, double-blind, placebo-controlled, phase 3 trial.", "citation": "Lim S, Buranapin S, Bao X et al. Once-weekly semaglutide 2·4 mg in an Asian population with obesity, defined as BMI ≥25 kg/m2, in South Korea and Thailand (STEP 11): a randomised, double-blind, placebo-controlled, phase 3 trial. The lancet. Diabetes & endocrinology. 2025.", "doi": "10.1016/S2213-8587(25)00164-0", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/40825340/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/40825340/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID40825340", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "STEP 11 found 16.0% versus 3.1% loss with 2.4 mg versus placebo at 44 weeks in Asian adults selected by BMI at least 25.", "what_it_does_not_show": "Some enrollment lies outside the fixed obesity eligibility; whole-cohort effects cannot supply an exact-scope microdose estimate.", "confounders_present": [ "Some enrollment lies outside the fixed obesity eligibility; whole-cohort effects cannot supply an exact-scope microdose estimate." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 50, "pmid": "41732031", "title": "Reduced-Frequency GLP1 Therapy Maintains Weight, Body Composition, and Metabolic Syndrome Improvements: A Case Series.", "citation": "Wong M, Wu A, Garhe PK et al. Reduced-Frequency GLP1 Therapy Maintains Weight, Body Composition, and Metabolic Syndrome Improvements: A Case Series. Obesity (Silver Spring, Md.). 2026.", "doi": "10.1002/oby.70137", "pmcid": "PMC13250739", "url": "https://pubmed.ncbi.nlm.nih.gov/41732031/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/41732031/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID41732031", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3", "SC5" ], "favors_models": [], "evidence_class": "Moderate", "system": "human observational", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "A 30-person retrospective series observed maintained weight/body composition after reducing dosing frequency, usually to every other week, at the existing dose.", "what_it_does_not_show": "Mixed agents, prior-plateau selection and no control do not test below-0.5 mg once-weekly maintenance against placebo; mass stabilization is not strength preservation.", "confounders_present": [ "Mixed agents, prior-plateau selection and no control do not test below-0.5 mg once-weekly maintenance against placebo; mass stabilization is not strength preservation." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "Pivotal test, including null or negative results and restricted contexts; this flag is not a positive threshold crossing.", "shared_components": [] }, { "n": 51, "pmid": "41068996", "title": "Impact of Semaglutide on fat mass, lean mass and muscle function in patients with obesity: The SEMALEAN study.", "citation": "Alissou M, Demangeat T, Folope V et al. Impact of Semaglutide on fat mass, lean mass and muscle function in patients with obesity: The SEMALEAN study. Diabetes, obesity & metabolism. 2026.", "doi": "10.1111/dom.70141", "pmcid": "PMC12673431", "url": "https://pubmed.ncbi.nlm.nih.gov/41068996/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/41068996/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID41068996", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC5" ], "favors_models": [], "evidence_class": "Moderate", "system": "human observational", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "SEMALEAN followed 115 adults prescribed 2.4 mg; 106 completers showed early lean loss followed by stabilization and improved grip strength.", "what_it_does_not_show": "Uncontrolled completion and dose selection cannot prove microdose protection; lean loss and functional decline are distinct outcomes.", "confounders_present": [ "Uncontrolled completion and dose selection cannot prove microdose protection; lean loss and functional decline are distinct outcomes." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "Pivotal test, including null or negative results and restricted contexts; this flag is not a positive threshold crossing.", "shared_components": [] }, { "n": 52, "pmid": "40631351", "title": "Semaglutide Therapy and Accelerated Sarcopenia in Older Adults with Type 2 Diabetes: A 24-Month Retrospective Cohort Study.", "citation": "Ren Q, Zhi L, Liu H. Semaglutide Therapy and Accelerated Sarcopenia in Older Adults with Type 2 Diabetes: A 24-Month Retrospective Cohort Study. Drug design, development and therapy. 2025.", "doi": "10.2147/DDDT.S531778", "pmcid": "PMC12235021", "url": "https://pubmed.ncbi.nlm.nih.gov/40631351/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/40631351/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID40631351", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC5" ], "favors_models": [], "evidence_class": "Moderate", "system": "human observational", "decisive_perturbation": true, "endogenous": false, "direction": "contradicts", "what_it_shows": "A retrospective older-diabetes cohort associated semaglutide with mass and functional decline compared with matched controls over 24 months.", "what_it_does_not_show": "Residual confounding, dose choice and comorbidity limit causality; the result does not show every dose causes harm or that microdosing prevents it.", "confounders_present": [ "Residual confounding, dose choice and comorbidity limit causality; the result does not show every dose causes harm or that microdosing prevents it." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "Pivotal test, including null or negative results and restricted contexts; this flag is not a positive threshold crossing.", "shared_components": [] }, { "n": 53, "pmid": "38218536", "title": "Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism.", "citation": "Nunn E, Jaiswal N, Gavin M et al. Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism. Molecular metabolism. 2024.", "doi": "10.1016/j.molmet.2024.101880", "pmcid": "PMC10832506", "url": "https://pubmed.ncbi.nlm.nih.gov/38218536/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/38218536/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID38218536", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC5" ], "favors_models": [], "evidence_class": "Moderate", "system": "animal model", "decisive_perturbation": true, "endogenous": true, "direction": "mixed", "what_it_shows": "Obese mice lost muscle and fat with semaglutide; adding an ActRII antibody preserved lean mass and improved exercise performance.", "what_it_does_not_show": "An added antibody and daily mouse exposure cannot establish human microdose protection; lean-mass correlation does not isolate function causally.", "confounders_present": [ "An added antibody and daily mouse exposure cannot establish human microdose protection; lean-mass correlation does not isolate function causally." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "Pivotal test, including null or negative results and restricted contexts; this flag is not a positive threshold crossing.", "shared_components": [] }, { "n": 54, "pmid": "37602204", "title": "GLP-1RA Liraglutide and Semaglutide Improves Obesity-Induced Muscle Atrophy via SIRT1 Pathway.", "citation": "Xiang J, Qin L, Zhong J et al. GLP-1RA Liraglutide and Semaglutide Improves Obesity-Induced Muscle Atrophy via SIRT1 Pathway. Diabetes, metabolic syndrome and obesity : targets and therapy. 2023.", "doi": "10.2147/DMSO.S425642", "pmcid": "PMC10439806", "url": "https://pubmed.ncbi.nlm.nih.gov/37602204/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/37602204/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID37602204", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC5" ], "favors_models": [], "evidence_class": "Moderate", "system": "animal model", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "Obese mice and myotubes showed less atrophy with liraglutide/semaglutide, with effects attenuated after SIRT1 inhibition.", "what_it_does_not_show": "Single-strain and cell-inhibitor results have system and specificity limits and do not establish weekly human microdose protection.", "confounders_present": [ "Single-strain and cell-inhibitor results have system and specificity limits and do not establish weekly human microdose protection." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] }, { "n": 55, "pmid": "34514682", "title": "Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss.", "citation": "Wharton S, Calanna S, Davies M et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes, obesity & metabolism. 2022.", "doi": "10.1111/dom.14551", "pmcid": "PMC9293236", "url": "https://pubmed.ncbi.nlm.nih.gov/34514682/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/34514682/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "STEP1-2-3-4-POOLED", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3", "SC4" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "Pooled STEP analyses found similar weight loss with and without gastrointestinal events; statistical mediation estimated little nausea-related contribution.", "what_it_does_not_show": "Postrandomization grouping is not mediator manipulation; nausea is not food noise, and pooled reports do not create microdose noninferiority.", "confounders_present": [ "Postrandomization grouping is not mediator manipulation; nausea is not food noise, and pooled reports do not create microdose noninferiority." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [ "STEP 1-NCT03548935", "STEP 2-NCT03552757", "STEP 3-NCT03611582", "STEP 4-NCT03548987" ] }, { "n": 56, "pmid": "40956259", "title": "Frailty and Effects of Semaglutide in Obesity-Related HFpEF: Findings From the STEP-HFpEF Program.", "citation": "Pandey A, Kitzman DW, Chinnakondepalli KM et al. Frailty and Effects of Semaglutide in Obesity-Related HFpEF: Findings From the STEP-HFpEF Program. JACC. Heart failure. 2025.", "doi": "10.1016/j.jchf.2025.102610", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/40956259/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/40956259/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "STEP-HFpEF-POOLED", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC5" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "Pooled STEP-HFpEF analyses found lower multidomain frailty burden with 2.4 mg and greater symptom benefit in the most frail baseline group.", "what_it_does_not_show": "A frailty index is not isolated muscle strength; the two shared parent trials cannot establish microdose protection.", "confounders_present": [ "A frailty index is not isolated muscle strength; the two shared parent trials cannot establish microdose protection." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [ "STEP-HFpEF-NCT04788511", "STEP-HFpEF-DM-NCT04916470" ] }, { "n": 57, "pmid": "42189538", "title": "Once-Weekly Semaglutide in Adults With Daily Cigarette Use: A Randomized Clinical Trial.", "citation": "Hendershot CS, Bremmer MP, Paladino MB et al. Once-Weekly Semaglutide in Adults With Daily Cigarette Use: A Randomized Clinical Trial. JAMA network open. 2026.", "doi": "10.1001/jamanetworkopen.2026.14898", "pmcid": "PMC13213524", "url": "https://pubmed.ncbi.nlm.nih.gov/42189538/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/42189538/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID42189538", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2", "SC4" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "A 24-person nine-week smoking trial found lower weight and nicotine craving despite null primary laboratory smoking interactions.", "what_it_does_not_show": "0.25 mg was only four-week titration before escalation; short exposure and nicotine craving cannot test food-noise necessity or weight maintenance.", "confounders_present": [ "0.25 mg was only four-week titration before escalation; short exposure and nicotine craving cannot test food-noise necessity or weight maintenance." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 58, "pmid": "41421448", "title": "Effect of semaglutide with metformin for weight loss and fertility in polycystic ovary syndrome (PCOS) patients with obesity: A pilot prospective study.", "citation": "Bolek T, Turňová P, Janošova S et al. Effect of semaglutide with metformin for weight loss and fertility in polycystic ovary syndrome (PCOS) patients with obesity: A pilot prospective study. Clinical nutrition ESPEN. 2026.", "doi": "10.1016/j.clnesp.2025.102885", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/41421448/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/41421448/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID41421448", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC5" ], "favors_models": [], "evidence_class": "Moderate", "system": "human observational", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "A 20-person PCOS cohort on metformin plus weekly 0.25-0.5 mg observed weight/fat loss and nonsignificant lean-mass change at five months.", "what_it_does_not_show": "Pooled doses, metformin and no placebo prevent isolation of below-0.5 mg causality; the reported weight endpoint precedes 24 weeks and BIA is not function.", "confounders_present": [ "Pooled doses, metformin and no placebo prevent isolation of below-0.5 mg causality; the reported weight endpoint precedes 24 weeks and BIA is not function." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "Pivotal test, including null or negative results and restricted contexts; this flag is not a positive threshold crossing.", "shared_components": [] }, { "n": 59, "pmid": "39375862", "title": "Semaglutide in patients with kidney failure and obesity undergoing dialysis and wishing to be transplanted: A prospective, observational, open-label study.", "citation": "Vanek L, Kurnikowski A, Krenn S et al. Semaglutide in patients with kidney failure and obesity undergoing dialysis and wishing to be transplanted: A prospective, observational, open-label study. Diabetes, obesity & metabolism. 2024.", "doi": "10.1111/dom.15967", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/39375862/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/39375862/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID39375862", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "A 13-person dialysis cohort observed 4.6 kg mean loss over 12 weeks with escalation from 0.25 to 0.5 to 1 mg.", "what_it_does_not_show": "Uncontrolled special-population exposure, short duration and mixed escalation do not test microdose maintenance.", "confounders_present": [ "Uncontrolled special-population exposure, short duration and mixed escalation do not test microdose maintenance." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 60, "pmid": "42857675", "title": "Comparison of cardiometabolic benefits and tolerability in patients on sustained low doses of semaglutide or tirzepatide.", "citation": "Murugadoss K, Venkatakrishnan AJ, Soundararajan V. Comparison of cardiometabolic benefits and tolerability in patients on sustained low doses of semaglutide or tirzepatide. Biology methods & protocols. 2026.", "doi": "10.1093/biomethods/bpag048", "pmcid": "PMC13651699", "url": "https://pubmed.ncbi.nlm.nih.gov/42857675/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/42857675/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-11-02", "status_checked_on": "2026-11-02", "study_id": "PMID42857675", "access_depth": "abstract_metadata", "access_note": "Original primary abstract and linked-status metadata examined via PubMed on 2026-11-02 during the second adversarial review; no complete-abstract, complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "human observational", "decisive_perturbation": true, "endogenous": false, "direction": "contradicts", "what_it_shows": "A federated EHR analysis identified 814 adults with at least three 0.25 mg-only semaglutide prescriptions spanning at least six months; mean 12-month weight change was -2.2% (versus -5.5% on sustained 2.5 mg tirzepatide).", "what_it_does_not_show": "Observational, uncontrolled for placebo and selected by prescription pattern, it is the closest real-world record of sustained sub-0.5 mg weekly exposure and does not show clinically meaningful (at least 5%) loss.", "confounders_present": [ "Observational, uncontrolled for placebo and selected by prescription pattern, it is the closest real-world record of sustained sub-0.5 mg weekly exposure and does not show clinically meaningful (at least 5%) loss." ], "verification": "verified", "verification_note": "Bounded source attribution added in the 2026-11-02 adversarial review (finding A1); not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "Pivotal test, including null or negative results and restricted contexts; this flag is not a positive threshold crossing.", "shared_components": [] }, { "n": 61, "pmid": "37424165", "title": "A model-based approach to predict individual weight loss with semaglutide in people with overweight or obesity.", "citation": "Strathe A, Horn DB, Larsen MS et al. A model-based approach to predict individual weight loss with semaglutide in people with overweight or obesity. Diabetes, obesity & metabolism. 2023.", "doi": "10.1111/dom.15211", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/37424165/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/37424165/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-11-02", "status_checked_on": "2026-11-02", "study_id": "PMID37424165", "access_depth": "abstract_metadata", "access_note": "Original primary abstract and linked-status metadata examined via PubMed on 2026-11-02 during the second adversarial review; no complete-abstract, complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": false, "direction": "mixed", "what_it_shows": "A population pharmacokinetic and exposure-response model built on the daily 0.05-0.4 mg dose-ranging trial and two weekly 2.4 mg phase 3 trials found that systemic exposure over time consistently explained weight-loss trajectories across trials and dosing regimens.", "what_it_does_not_show": "A sponsor model of exposure, not a randomized test of sustained sub-0.5 mg weekly maintenance; it makes the 0.05 mg daily arm the closest exposure-matched randomized evidence but does not override the preregistered exclusion of daily-to-weekly conversion.", "confounders_present": [ "A sponsor model of exposure, not a randomized test of sustained sub-0.5 mg weekly maintenance; it makes the 0.05 mg daily arm the closest exposure-matched randomized evidence but does not override the preregistered exclusion of daily-to-weekly conversion." ], "verification": "verified", "verification_note": "Bounded source attribution added in the 2026-11-02 adversarial review (finding A2); not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "Pivotal test, including null or negative results and restricted contexts; this flag is not a positive threshold crossing.", "shared_components": [] } ], "verification_summary": { "load_bearing_claims_checked": 67, "verified": 67, "unverified": 0, "contradicted": 0, "note": "Verified attribution is distinct from mechanism truth or complete body access." }, "factual_issues_found": [], "cap_rules_applied": [ { "subclaim_id": "SC1", "cap": "Γ", "cap_source": "universal", "triggered": true, "trigger_text_quoted": "Biomarker change without functional/phenotypic change caps at Γ.", "specific_trigger": "Weekly dose-finding included 0.1-0.8 mg without escalation over 12 weeks in diabetes, supporting exposure-response plausibility. Its examined abstract does not isolate low-arm appetite effects, and glycemic change alone is not a clinical phenotype crossing. The 1/2.4 mg and oral appetite experiments cannot establish sustained engagement of both registered pathways under the strict microdose maintenance exposure.", "resulting_ceiling": "Γ" }, { "subclaim_id": "SC5", "cap": "Γ", "cap_source": "rubric", "triggered": true, "trigger_text_quoted": "Mechanistic plausibility plus one-species or in vitro support caps at Γ.", "specific_trigger": "Animal atrophy and co-treatment experiments plus mixed human functional observations support a possible muscle-related pathway. No direct human microdose comparison demonstrates prevention of clinically important strength or function loss. SEMALEAN grip improvement at 2.4 mg is uncontrolled; retrospective older-diabetes decline is confounded; MRI/DXA mass changes and relative lean proportion cannot substitute for function.", "resulting_ceiling": "Γ" } ], "cap_precedence_resolutions": [ { "collision": "Perturbation in a defined setting versus broader inference", "subclaim_scope_cap_binds_on": "Once-weekly injectable semaglutide maintenance doses below 0.5 mg cause clinically meaningful sustained weight loss in adults with overweight or obesity.", "subclaim_scope_threshold_binds_on": "The precise experimentally tested subclaim scope", "resolution": "The positive clinical trials cross within their tested 0.5/1/1.7/2.4 mg or other schedules. Their result cannot cross the strict below-0.5 mg weekly maintenance SC2 by class inference. Animal and biomarker results preserve experimental scope; no universal weak-leg cap is reapplied to a complementary same-scope set.", "note": "Convergent lines are assessed as a set; one weak leg is not re-capped over the assembled case." } ], "boundary_check_BGD": [ { "subclaim_id": "SC1", "field_valid_perturbation_quote": "\n- Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension\n- Must separate developmental effects from true aging effects\n- Biomarker change alone does NOT satisfy this threshold", "qualifying_evidence_present": "no", "qualifying_evidence_citation": "", "gamma_hard_rules_triggered": [ "Low-arm glycemic/partial-system support does not prove the complete registered engagement claim." ], "disease_phenotype_relevance": "yes", "perturbation_result_positive": "no", "perturbation_result_note": "Weekly dose-finding included 0.1-0.8 mg without escalation over 12 weeks in diabetes, supporting exposure-response plausibility. Its examined abstract does not isolate low-arm appetite effects, and glycemic change alone is not a clinical phenotype crossing. The 1/2.4 mg and oral appetite experiments cannot establish sustained engagement of both registered pathways under the strict microdose maintenance exposure.", "ceiling_from_boundary_check": "Γ" }, { "subclaim_id": "SC2", "field_valid_perturbation_quote": "\n- Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension\n- Must separate developmental effects from true aging effects\n- Biomarker change alone does NOT satisfy this threshold", "qualifying_evidence_present": "no", "qualifying_evidence_citation": "", "gamma_hard_rules_triggered": [ "No positive exact-dose and horizon clinical perturbation was examined." ], "disease_phenotype_relevance": "yes", "perturbation_result_positive": "no", "perturbation_result_note": "No examined randomized original assigns strictly below 0.5 mg weekly maintenance versus placebo for at least 5% loss at 24-68 weeks in the registered BMI-defined population. Twelve-week weekly dose-finding is too short; daily dose-ranging has another schedule; 0.5/1/2.4 mg trials have another maintenance exposure. Small mixed-dose and cointervention cohorts provide partial support without a clean exact-scope causal perturbation. This is an evidence gap, not proof that microdosing cannot work. The largest on-exposure record, a federated EHR cohort of 814 adults on sustained 0.25 mg-only prescriptions (PMID 42857675), observed -2.2% mean 12-month weight change; being observational, without placebo and prescription-selected, it leans against the claim without supplying the missing placebo-controlled test.", "ceiling_from_boundary_check": "Γ" }, { "subclaim_id": "SC3", "field_valid_perturbation_quote": "\n- Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension\n- Must separate developmental effects from true aging effects\n- Biomarker change alone does NOT satisfy this threshold", "qualifying_evidence_present": "no", "qualifying_evidence_citation": "", "gamma_hard_rules_triggered": [ "No direct equivalence and fewer-harms experiment was examined." ], "disease_phenotype_relevance": "yes", "perturbation_result_positive": "no", "perturbation_result_note": "Comparable weight and clinical benefits to 2.4 mg plus fewer adverse effects is not established by a direct randomized noninferiority/benefit-harm contrast. Final-dose observational nulls are not equivalence tests. A lower-dose tolerability hypothesis has biological rationale but the full positive equivalence conjunction remains speculative; exact-dose clinical data are missing.", "ceiling_from_boundary_check": "Γ" }, { "subclaim_id": "SC4", "field_valid_perturbation_quote": "\n- Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension\n- Must separate developmental effects from true aging effects\n- Biomarker change alone does NOT satisfy this threshold", "qualifying_evidence_present": "no", "qualifying_evidence_citation": "", "gamma_hard_rules_triggered": [ "No food-noise necessity experiment was examined." ], "disease_phenotype_relevance": "yes", "perturbation_result_positive": "no", "perturbation_result_note": "Randomized semaglutide experiments establish changes in intake, appetite and some reward measures; validated food-noise measurements in the examined semaglutide survey remain retrospective and descriptive. In a 60-week trial, measured intake differences persist at 20/40/60 weeks while hunger and food-preoccupation contrasts lose significance after week 20; food-reward responsiveness (Power of Food Scale), the measure closest to the food-noise construct, still differed at week 40, and only at week 60 did no subjective contrast remain. This narrows an obligatory subjective pathway but does not directly remove the validated construct. Necessary food-noise mediation remains partial-system plausibility, not a demonstrated dependency.", "ceiling_from_boundary_check": "Γ" }, { "subclaim_id": "SC5", "field_valid_perturbation_quote": "\n- Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension\n- Must separate developmental effects from true aging effects\n- Biomarker change alone does NOT satisfy this threshold", "qualifying_evidence_present": "no", "qualifying_evidence_citation": "", "gamma_hard_rules_triggered": [ "Experimental animal support cannot establish human microdose function prevention." ], "disease_phenotype_relevance": "yes", "perturbation_result_positive": "no", "perturbation_result_note": "Animal atrophy and co-treatment experiments plus mixed human functional observations support a possible muscle-related pathway. No direct human microdose comparison demonstrates prevention of clinically important strength or function loss. SEMALEAN grip improvement at 2.4 mg is uncontrolled; retrospective older-diabetes decline is confounded; MRI/DXA mass changes and relative lean proportion cannot substitute for function.", "ceiling_from_boundary_check": "Γ" } ], "thresholds_tested": [ { "subclaim_id": "SC1", "threshold": "Δ", "requirement_quoted": "Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.", "satisfied": "no", "supporting_evidence": [], "what_would_cross_it": "Publish arm-specific appetite, intake, exposure and metabolic effects under sustained sub-0.5 mg weekly maintenance, with matched controls and functional outcomes." }, { "subclaim_id": "SC2", "threshold": "Δ", "requirement_quoted": "Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.", "satisfied": "no", "supporting_evidence": [], "what_would_cross_it": "Randomize baseline-defined eligible adults to specified sub-0.5 mg weekly maintenance, placebo and standard exposure, with prespecified 24-68-week weight outcomes and no responder-defined exclusions." }, { "subclaim_id": "SC3", "threshold": "Δ", "requirement_quoted": "Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.", "satisfied": "no", "supporting_evidence": [], "what_would_cross_it": "Conduct a prospectively powered direct noninferiority trial versus 2.4 mg using a clinically justified margin and simultaneous adverse-event, discontinuation and functional endpoints." }, { "subclaim_id": "SC4", "threshold": "Δ", "requirement_quoted": "Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.", "satisfied": "no", "supporting_evidence": [], "what_would_cross_it": "Manipulate or independently dissociate validated food-noise change from drug exposure and intake, while preserving objective weight outcomes and checking mediator-outcome confounding." }, { "subclaim_id": "SC5", "threshold": "Δ", "requirement_quoted": "Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.", "satisfied": "no", "supporting_evidence": [], "what_would_cross_it": "Measure grip/leg strength, walking/chair stands, muscle quality, nutrition and DXA under randomized exact-dose exposure with age/diabetes strata." } ], "generalization_check": { "generalization_tested": "no", "context_boundary_mapped": "yes", "internal_negative_controls": [ "Daily semaglutide schedule versus weekly registration.", "Titration-only 0.25 mg followed by escalation in SUSTAIN 9 and smoking trials.", "Persistent objective intake/weight changes despite nonsignificant late appetite/food-preoccupation contrasts.", "Conflicting controlled/observational function endpoints and absolute-versus-relative lean mass.", "Final-dose assignment driven by satisfactory prior response in FLEX-SEMA." ], "note": "Exact microdose clinical generalization is untested, rather than a demonstrated exact-dose effect with a mapped boundary. Standard-dose contexts span diabetes, non-diabetes, East Asian enrollment, HFpEF, osteoarthritis and CKD, with different endpoints and horizons. These real benefits are retained and cannot be borrowed by sub-0.5 mg claims. Prior-response selection is not a baseline scope restriction." }, "falsification_patterns_met": [ { "pattern": "Necessary subjective food-noise explanation faces an objective-subjective dissociation", "evidence": "In PMID 42323166, intake differences persist at 20/40/60 weeks while hunger and food-preoccupation contrasts lose significance after week 20; food-reward responsiveness (Power of Food Scale), the measure closest to the food-noise construct, still differed at week 40 and only at week 60 did no subjective contrast remain. This is not the same instrument as FNQ and does not directly ablate it.", "downgrade_applied": false }, { "pattern": "Strict microdose equivalence has not passed a direct test", "evidence": "Approved-dose trials and uncontrolled final-dose nulls are not direct microdose noninferiority. No experimental falsification of exact-dose efficacy was examined. Randomised dose-response evidence nevertheless runs against comparability: weight loss rose monotonically from 0.05 to 0.4 mg daily, weekly dose-finding was dose dependent, and 2.0 mg exceeded 1.0 mg weekly (trial-product estimand), while gastrointestinal events were dose related. Lower doses plausibly reduce adverse effects but, on every randomised dose comparison examined, also reduce weight loss.", "downgrade_applied": false } ], "pitfalls_flagged": [ { "pitfall": "Selective generalization", "where": "Daily, oral and 0.5/1/2.4 mg effects cannot establish strict weekly microdose maintenance." }, { "pitfall": "Therapeutic effect misread as mechanistic proof", "where": "Drug-induced appetite/intake and weight changes do not prove necessary food-noise mediation." }, { "pitfall": "Confirmation by biomarker", "where": "Lean mass and its percentage are not strength or clinically important dysfunction." }, { "pitfall": "Scope fitted to outcome", "where": "Plateau achievers and satisfactory-response dose selection cannot define baseline microdose efficacy scope." }, { "pitfall": "Replication confused with independence", "where": "Secondary STEP/SUSTAIN and pooled reports share parent trials." } ], "causal_tally_audit": { "tally_claimed_by_document": 0, "tally_after_audit": 0, "tally_unit": "Positive qualifying study units across scoped subclaims, not independent causal lines or full-claim necessity/sufficiency.", "screened_discriminating_contrasts": 11, "items_rejected": [ "Null and negative contrasts are discriminators, not positive threshold crossings. Reports and replications are not independent causal lines.", "Zero positive exact-scope SC2 trial units were examined; comparator positives do not count as microdose causal crossings.", "Short weekly dose-finding is direct-dose-adjacent, not a 24-68-week clinical result.", "Pooled and secondary reports share parent studies; observed function and muscle mass differ." ] }, "steelman": { "case_one_rung_higher": "Δ could be defended because weekly dose-finding includes genuine low-dose arms and lower/mixed-dose cohorts report weight loss. The strongest version would need arm-specific sustained clinical results within the preregistered dose, comparator, baseline eligibility and 24-68-week horizon. Its strongest upward argument is exposure matching: a sponsor exposure-response model (PMID 37424165) found that systemic exposure, not schedule, explained weight trajectories across the daily 0.05-0.4 mg and weekly 2.4 mg trials, making the 0.05 mg daily arm (0.35 mg per week cumulatively; -6.0% versus -2.3% placebo at 52 weeks) the closest exposure-matched randomised evidence. The preregistered scope nevertheless excludes daily-to-weekly conversion.", "case_one_rung_lower": "Β could be defended if the only relevant evidence were uncontrolled weight-loss observations. That undercounts direct short weekly dose-finding and established semaglutide pharmacological plausibility, while properly admitting that these do not establish the long-horizon claim.", "which_rejected": "Reject Δ because no positive matched exact-scope maintenance experiment was examined; daily and approved-dose evidence cannot repair the missing clinical test. Reject Β because partial direct dose-finding and mechanistic pharmacology support more than co-occurrence. Retain Γ with Moderate appraisal confidence.", "blocking_cap_threshold_or_missing_experiment": "Missing experiment: A blinded randomized study in baseline-defined adults meeting the registered BMI criteria, stratified by diabetes, assigns a specified weekly injectable maintenance exposure below 0.5 mg, matched placebo and 2.4 mg with identical behavioral support. Prespecify 52-week weight change and at least 5% responder status, estimands, missingness, adverse events and objective strength/function. A separately randomized de-escalation arm can test maintenance after standard-dose loss without redefining the initial-treatment claim." }, "final_score": { "hsef_level": "Γ", "hsef_descriptor": "Mechanistically plausible, partial system support", "confidence": "Moderate", "confidence_rationale": "59 primary reports examined. Moderate rests on evidence density and reproducibility, not on reading access: no study tests the registered sub-0.5 mg weekly maintenance exposure at all, the nearest dose-adjacent reports are uncontrolled and response-selected, functional and muscle outcomes conflict across uncontrolled cohorts, and food-noise measurement is recall-based. Confidence bounds the evidence base, not correctness.", "rests_on_non_peer_reviewed_work": false, "rationale": "The preregistered primary-subclaim rule returns Γ from SC2. Fifty-nine relevant original reports were examined, but none directly supplies the registered below-0.5 mg weekly, 24-68-week placebo-controlled maintenance experiment. Standard-dose clinical success is preserved as a different proposition. Lower-dose anecdotes, daily dose-ranging and titration do not replace the missing exposure-specific test." }, "role_of_mechanism": { "classification": "epiphenomenon", "derivation_step_matched": 2, "derivation": "For the exact registered microdose mechanism, no demonstrated causal dependency in either direction was examined, so step 2 selects the framework category epiphenomenon. This coarse label records absent exact-scope dependency, not demonstrated biological inertness and not the role of higher-dose semaglutide, whose clinical effects are directly established. The label means a causal role is not established by the evidence, not that the intervention has no effect.", "tournament_used_as_tiebreaker": false, "note": "Derived from causal direction, not tournament rank." }, "extended_scoring_MSD": { "momentum": { "value": "Associational only", "artifact": "The exact-dose-adjacent recent originals are FLEX-SEMA, INFORM, the reduced-frequency case series and the small mixed-dose PCOS cohort. Recent randomized clinical work tests standard or higher doses rather than the strict microdose maintenance boundary. No verified named pending exact-dose trial was identified in this bounded search. The largest recent on-exposure record is observational: a 2026 federated EHR cohort (PMID 42857675) of 814 adults on sustained 0.25 mg-only semaglutide observed -2.2% mean 12-month weight change, below the 5% threshold.", "justification": "The exact-dose-adjacent recent originals are FLEX-SEMA, INFORM, the reduced-frequency case series and the small mixed-dose PCOS cohort. Recent randomized clinical work tests standard or higher doses rather than the strict microdose maintenance boundary. No verified named pending exact-dose trial was identified in this bounded search. The largest recent on-exposure record is observational: a 2026 federated EHR cohort (PMID 42857675) of 814 adults on sustained 0.25 mg-only semaglutide observed -2.2% mean 12-month weight change, below the 5% threshold." }, "stability": { "value": "Stable", "trigger": "No verified named pending randomized sub-0.5 mg weekly maintenance result was identified. A future exact-dose placebo trial could raise SC2 or confirm a null, but a generic hypothetical experiment is not a named pending trigger. Named de-escalation trials are registered (REST, NCT07294950, gradual reduction vs cessation, primary completion 2028-09; NCT07783854, tapering vs maintenance non-inferiority, primary completion 2027-12). They test tapering from 1-1.7 mg, not sustained sub-0.5 mg maintenance versus placebo, so Stability remains Stable.", "justification": "No verified named pending randomized sub-0.5 mg weekly maintenance result was identified. A future exact-dose placebo trial could raise SC2 or confirm a null, but a generic hypothetical experiment is not a named pending trigger. Named de-escalation trials are registered (REST, NCT07294950, gradual reduction vs cessation, primary completion 2028-09; NCT07783854, tapering vs maintenance non-inferiority, primary completion 2027-12). They test tapering from 1-1.7 mg, not sustained sub-0.5 mg maintenance versus placebo, so Stability remains Stable." }, "divergence": { "implied_level": null, "implied_level_basis": "Clinical trial literature, low-dose tailoring reports and online food-noise promotion describe different propositions; no measured single field-implied letter applies.", "assessed_level": "Γ", "gap_in_rungs": null, "value": "Contested", "justification": "No competent-reader ladder survey or manufactured numeric belief gap is claimed." }, "calibration_note": "M/S/D never modify HSEF level or confidence." }, "change_record": { "applies": false, "prior_level": "none assigned", "prior_confidence": null, "prior_source": null, "derived_before_consulting_prior": true, "new_level": "Γ", "direction": "newly assigned", "what_moved_it": "Fresh primary evidence appraisal; not blinded.", "divergence_from_other_reviewers": null }, "proposed_decisive_experiments": [ { "name": "Registered boundary experiment", "experiment": "A blinded randomized study in baseline-defined adults meeting the registered BMI criteria, stratified by diabetes, assigns a specified weekly injectable maintenance exposure below 0.5 mg, matched placebo and 2.4 mg with identical behavioral support. Prespecify 52-week weight change and at least 5% responder status, estimands, missingness, adverse events and objective strength/function. A separately randomized de-escalation arm can test maintenance after standard-dose loss without redefining the initial-treatment claim.", "readout": "Percent weight change and at least 5% responders at 52 weeks; simultaneous adverse events/discontinuation, validated FNQ, measured intake and objective strength/walking outcomes.", "critical_control": "Matched formulation, exposure verification, counseling, follow-up and estimands; retain nonresponders and discontinuers, separate initiation from post-loss de-escalation, and use blinded independent outcome measurement.", "supporting_result": "A prespecified positive placebo contrast establishes the first exact-scope clinical crossing; comparator noninferiority with fewer clinically important harms separately supports SC3.", "falsifying_result": "No clinically meaningful placebo advantage narrows the efficacy claim without refuting higher-dose semaglutide; inferior weight or function with modest tolerability improvement falsifies promoted equivalence." } ], "knowledge_gaps": [ { "name": "Gap 1", "statement": "Direct randomized below-0.5 mg weekly maintenance at 24-68 weeks in the registered baseline BMI population.", "relevance": "Limits mechanism identification or scope." }, { "name": "Gap 2", "statement": "Separate low-dose initiation from de-escalation after successful higher-dose loss; retain response/tolerance selection explicitly. Registered de-escalation trials (REST, NCT07294950; NCT07783854) test tapering from 1-1.7 mg, not sustained sub-0.5 mg maintenance versus placebo.", "relevance": "Limits mechanism identification or scope." }, { "name": "Gap 3", "statement": "Matched noninferiority and simultaneous benefit-harm comparison against 2.4 mg, rather than final-dose observational nulls.", "relevance": "Limits mechanism identification or scope." }, { "name": "Gap 4", "statement": "Prospective validated food-noise measurement and necessary-mediator testing distinct from appetite, cravings, nausea and one-meal intake.", "relevance": "Limits mechanism identification or scope." }, { "name": "Gap 5", "statement": "Integrated absolute muscle mass, muscle quality, objective strength/function and nutrition across baseline age/diabetes strata.", "relevance": "Limits mechanism identification or scope." }, { "name": "Gap 6", "statement": "Arm-specific low-dose phase 2 data and independent checking of complete bodies/supplements; three selected partial-body checks do not constitute a full-paper audit.", "relevance": "Limits mechanism identification or scope." } ], "review_metadata": { "review_date": "2026-10-13", "reviewer": "Codex", "evidence_base_note": "59 primary reports; literature cutoff 2026-10-13; source examination UTC date 2026-10-13; bounded critical review, not exhaustive systematic review.", "literature_tools_available": true, "literature_tools_note": "Life Sciences Literature PubMed/Entrez, separately logged public original-body retrieval, and Consensus Pro browser searches. Provider output retained as observed browser text with citation-link mappings, or as previously exported connector documents where present. AI synthesis is not primary full-text verification. Consensus retrieved/included counts are not examined-primary counts. Scite monthly limit was reached earlier in this session; no new Scite query or incoming citation-context audit is claimed for these cases. Tool receipts record actual use. Supplementary discovery outputs do not earn primary-count credit. No independent blinded review.", "skill_version": "5.3", "validator_run": "PASS: exact archived HSEF v5.3 validator rerun after final sealing.", "validator_warnings_addressed": "No warnings.", "limits": "Bounded source-based critical review; no complete-paper/supplement audit, independent scientific peer review or blinded calibration. Revision cases retain original prose outside the three framework output blocks and have explicit correction logs.", "adversarial_review": { "reviewer": "Claude Opus 5.5 (Anthropic)", "date": "2026-11-02", "pass": "second adversarial (red-team) pass", "prior_pass": "Claude Opus 5.5 (Anthropic), 2026-10-14, GM-1 to GM-4", "record": "ADVERSARIAL_REVIEW.glp1-microdosing.md; adversarial-findings.glp1-microdosing.json", "findings_applied": [ "A1", "A2", "A3", "A4", "A5", "A6", "A7", "A8", "A9", "A10", "A11" ], "level_before": "Γ", "level_after": "Γ", "confidence_before": "Moderate", "confidence_after": "Moderate", "sources_added": [ "PMID 42857675 (A1)", "PMID 37424165 (A2)" ], "note": "The original audit examined 59 primary reports; two further originals were added and verified at abstract depth in this pass. Corrections applied under the PI's authorisation; level and confidence unchanged." } }, "is_calibration_entry": { "value": false, "entry_role": "not_calibration", "blind_graded": null, "completed_blinded_calibration": false, "expected_band_sealed_at": "", "target_sha256": "", "target_authorship": "not applicable", "target_author_saw_review": null, "future_run_status": "not prepared", "unblinded_reason": "These topic families were selected from an editorial traffic-priority list. Selection was visible; no blind calibration or predetermined clinical verdict was preregistered." }, "upper_ladder_check": { "final_level_below_zeta": true, "equivalents_considered": [ { "kind": "mendelian_randomization", "available": false, "why_not_sufficient": "Therapeutic dose assignment and withdrawal are feasible and represented at higher doses; none supplies the precise registered microdose experiment. Natural/genetic exposure lines do not establish this administered-dose sufficiency or equivalence. The ladder is reachable through the proposed exact-dose controlled study; missing evidence is not an unreachable requirement." }, { "kind": "natural_experiment", "available": false, "why_not_sufficient": "Therapeutic dose assignment and withdrawal are feasible and represented at higher doses; none supplies the precise registered microdose experiment. Natural/genetic exposure lines do not establish this administered-dose sufficiency or equivalence. The ladder is reachable through the proposed exact-dose controlled study; missing evidence is not an unreachable requirement." }, { "kind": "dose_response_across_populations", "available": false, "why_not_sufficient": "Therapeutic dose assignment and withdrawal are feasible and represented at higher doses; none supplies the precise registered microdose experiment. Natural/genetic exposure lines do not establish this administered-dose sufficiency or equivalence. The ladder is reachable through the proposed exact-dose controlled study; missing evidence is not an unreachable requirement." }, { "kind": "withdrawal_rechallenge", "available": true, "why_not_sufficient": "Therapeutic dose assignment and withdrawal are feasible and represented at higher doses; none supplies the precise registered microdose experiment. Natural/genetic exposure lines do not establish this administered-dose sufficiency or equivalence. The ladder is reachable through the proposed exact-dose controlled study; missing evidence is not an unreachable requirement." }, { "kind": "therapeutic_perturbation_hard_endpoint", "available": false, "why_not_sufficient": "Therapeutic dose assignment and withdrawal are feasible and represented at higher doses; none supplies the precise registered microdose experiment. Natural/genetic exposure lines do not establish this administered-dose sufficiency or equivalence. The ladder is reachable through the proposed exact-dose controlled study; missing evidence is not an unreachable requirement." } ], "convergence_present": false, "cap_reapplied_to_convergent_set": false }, "provenance_header": { "sources_total": 61, "claims_total": 67, "claims_verified": 67, "claims_unverified": 0, "claims_contradicted": 0, "tier_a_sources": 61, "generated_by": "Codex; HSEF v5.3", "gate_passed": true }, "claims": [ { "id": "C1", "text": "Randomized 52-week obesity trial found 6.0%-13.8% loss with 0.05-0.4 mg DAILY semaglutide versus 2.3% placebo; gastrointestinal events were dose related. Every active semaglutide dose was administered daily; the trial does not test sub-0.5 mg weekly maintenance or permit arithmetic conversion of exposures.", "carries_number": true, "load_bearing_for": [ "SC1", "SC2", "SC3" ], "source_ns": [ 1 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C2", "text": "FLEX-SEMA documented response-selected flexible dosing; 5.4% remained on 0.25 mg at three months, and the original body distinguishes cumulative six-month responders from weight-loss bins. The same source reports adverse events in 56.8% of patients at three months and 32.6% at six months, early discontinuation rising from 6.3% to 10.5%, and dose maintenance attributed to satisfactory results (40%), cost (30%) and adverse events (27.5%). No exact long-term below-0.5 mg placebo contrast; satisfactory prior response drives dose maintenance. Indexed abstract mislabels bin percentages as cumulative thresholds, so original body governs.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 2 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:MATERIALS AND METHODS:paragraph0, 1:MATERIALS AND METHODS:paragraph1, 1:MATERIALS AND METHODS:paragraph7, 1:MATERIALS AND METHODS:paragraph8, 2:RESULTS:paragraph1, 2:RESULTS:paragraph3, 2:RESULTS:paragraph14, 2:RESULTS:paragraph15, 2:RESULTS:paragraph16, 2:RESULTS:paragraph19. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C3", "text": "Thirty-person randomized crossover at 12 weeks and 1 mg weekly reduced daily ad-libitum intake 24% and body weight 5 kg with altered appetite and food cravings. Dose escalated to 1 mg; early 0.25 mg titration is not isolated; eating-control measures are not necessary food-noise mediator perturbations.", "carries_number": true, "load_bearing_for": [ "SC1", "SC4" ], "source_ns": [ 3 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C4", "text": "Secondary randomized tirzepatide 15 mg versus semaglutide 1 mg versus placebo analysis found greater weight/fat loss with tirzepatide despite similar measured appetite and meal-intake changes between drugs. One meal/intake instrument does not isolate full energy balance or validated food-noise necessity; no microdose or muscle-function prevention tested.", "carries_number": true, "load_bearing_for": [ "SC3", "SC4", "SC5" ], "source_ns": [ 4 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C5", "text": "Seventy-two-person randomized 20-week trial of 2.4 mg weekly reduced intake 35%, weight 9.9% and hunger/cravings versus placebo; no late gastric-emptying delay by indirect test. No sub-0.5 mg maintenance or specific food-noise mediator manipulation; paracetamol absorption is an indirect gastric-emptying instrument.", "carries_number": true, "load_bearing_for": [ "SC1", "SC4" ], "source_ns": [ 5 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C6", "text": "Randomized 61-person 20-week oral 50 mg trial reduced energy intake and appetite with 9.8% weight loss versus 1.5% placebo. Oral daily bioavailability and exposure differ from weekly injectable microdoses; appetite changes do not prove necessary food-noise mediation.", "carries_number": true, "load_bearing_for": [ "SC1", "SC4" ], "source_ns": [ 6 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C7", "text": "Small crossover oral 14 mg daily trial in T2D reduced evaluated daily intake 38.9% and weight 2.7 kg versus 0.1 kg placebo with mixed meal-context appetite responses. Thirteen evaluable subjects and oral formulation cannot establish weekly microdose maintenance; no mediator ablation.", "carries_number": true, "load_bearing_for": [ "SC1", "SC4" ], "source_ns": [ 7 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C8", "text": "Randomized 120-person 60-week 2.4 mg trial sustained lower lunch intake at 20/40/60 weeks while hunger and food-preoccupation contrasts lost significance after week 20; food-reward responsiveness (Power of Food Scale), the measure closest to the food-noise construct, still differed at week 40, and only at week 60 did no subjective contrast remain. Subjective appetite and food-preoccupation dissociation narrows simple mediation, but does not directly remove validated food noise or test microdoses.", "carries_number": true, "load_bearing_for": [ "SC1", "SC4" ], "source_ns": [ 8 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Methods:paragraph0, 1:Methods:paragraph1, 1:Methods:paragraph3, 1:Methods:paragraph4, 1:Methods:paragraph8, 1:Methods:paragraph12, 2:Results:paragraph8, 2:Results:paragraph10, 2:Results:paragraph19, 2:Results:paragraph21, 2:Results:paragraph22. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C9", "text": "STEP 1 randomized 1961 eligible non-diabetic adults to 2.4 mg weekly; 68-week mean weight loss 14.9% versus 2.4% placebo and 5% responders 86.4% versus 31.5%. Drug efficacy at 2.4 mg with lifestyle support does not cross sub-0.5 mg maintenance threshold; participant-reported function does not isolate muscle preservation.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3", "SC5" ], "source_ns": [ 9 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C10", "text": "STEP 6 compared 2.4/1.7 mg weekly with placebo in 401 East Asian adults; 68-week mean losses 13.2/9.6% versus 2.1%, mapping a dose/context boundary. Both doses greatly exceed microdose definition; visceral-fat imaging does not establish muscle function or microdose equivalence.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3", "SC5" ], "source_ns": [ 10 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C11", "text": "STEP UP MRI subset pooled 49 semaglutide 7.2/2.4 mg versus 6 placebo showed less fat infiltration and preserved sit-to-stand repetitions despite volume loss. Tiny imbalanced subset with same 13-to-15 chair stands in both groups gives no positive microdose muscle-function prevention result; 72 weeks lies beyond registered weight horizon.", "carries_number": true, "load_bearing_for": [ "SC5" ], "source_ns": [ 11 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C12", "text": "SUSTAIN 7 randomized 1201 T2D patients; 0.5/1 mg weekly reduced weight 4.6/6.5 kg versus 2.3/3 kg dulaglutide at 40 weeks. 0.5 mg is explicitly excluded by strict below 0.5 mg registration; no placebo or matched 2.4 mg microdose-equivalence comparison.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 12 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C13", "text": "STEP UP T2D randomized 512 adults to 7.2/2.4 mg or placebo; 7.2 mg produced 13.2% versus 3.9% loss with dose-related dysaesthesia imbalance. No sub-0.5 mg maintenance; 72-week horizon and parent-linked correction 41932351 must remain explicit; no muscle prevention outcome here.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3", "SC5" ], "source_ns": [ 13 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C14", "text": "STEP-HFpEF DM secondary analysis found 2.4 mg weekly improved symptom/physical-limitations scores and weight across baseline HbA1c strata in 616 adults. Heart-failure function is not dose-specific muscle-strength preservation; subgroup report shares parent trial and does not test microdose maintenance.", "carries_number": true, "load_bearing_for": [ "SC2", "SC5" ], "source_ns": [ 14 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C15", "text": "SOUL posthoc secondary analysis of 9650 randomized high-risk T2D adults found oral 14 mg exposure improved multiple risk factors and weight beyond placebo over 156 weeks. Oral exposure, long horizon and surrogate contrasts do not establish weekly microdose benefits or comparable clinical benefit-harm profile.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 15 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C16", "text": "Forty-person retrospective obesity series found observed loss at 3 months and in 25 six-month completers; maintenance was 1 mg in 16 and 2 mg in 9. Lower-than-obesity-dose is not below 0.5 mg; uncontrolled attrition/completion and dose selection preclude microdose causality or noninferiority.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 16 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C17", "text": "Qualitative interviews with 30 current/former GLP1 users describe reduced food noise, adverse effects, cost barriers and lifestyle facilitation. Recruited testimonials without randomized mediator contrast cannot demonstrate necessary food-noise mechanism or exact-dose efficacy.", "carries_number": true, "load_bearing_for": [ "SC4" ], "source_ns": [ 17 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C18", "text": "Surveys/video diaries among 1659 virtual-care participants describe reduced food thoughts and satiety alongside cost, stigma and side-effect discontinuation. Mixed drugs and self-report with selection do not isolate semaglutide microdose effects or causal necessity of food-noise reduction.", "carries_number": true, "load_bearing_for": [ "SC4" ], "source_ns": [ 18 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C19", "text": "INFORM reported lower remembered-to-current FNQ scores in 550 semaglutide users; original Methods/Results confirm 547 complete FNQ responses and descriptive analysis without statistical tests. Recall, panel selection and mixed doses including 2.4 mg do not establish necessary mediation or exact microdose efficacy.", "carries_number": true, "load_bearing_for": [ "SC4" ], "source_ns": [ 19 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 2:Methods:paragraph1, 2:Methods:paragraph3, 2:Methods:paragraph4, 2:Methods:paragraph5, 2:Methods:paragraph11, 2:Methods:paragraph13, 3:Results:paragraph0, 3:Results:paragraph1, 3:Results:paragraph4. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C20", "text": "Cross-sectional 79-person GLP1RA study associated 6-month use with lower FNQ, food reward and intake; protein intake did not differ significantly. Separate exposure groups and mixedagents/doses do not establish longitudinal mediation or muscle-strength preservation.", "carries_number": true, "load_bearing_for": [ "SC4", "SC5" ], "source_ns": [ 20 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C21", "text": "Original 99-video TikTok analysis found food-noise content dominated by patient testimony and usually positive medication portrayals. Engagement and reported experience describe promotion, not causal clinical efficacy; no field-wide HSEF belief survey or microdose comparison.", "carries_number": true, "load_bearing_for": [ "SC4" ], "source_ns": [ 21 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C22", "text": "The 415-person randomized 12-week phase 2 study tested weekly 0.1-0.8 mg without escalation and higher escalated doses; glycemic and weight responses were dose dependent. The abstract reports the largest weight effect at 1.6 mg without low-arm estimates; neither duration nor eligibility establishes the registered 24-68-week clinical claim.", "carries_number": true, "load_bearing_for": [ "SC1", "SC2", "SC3" ], "source_ns": [ 22 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C23", "text": "SUSTAIN 1 found 3.73/4.53 kg weight loss with weekly 0.5/1 mg versus 0.98 kg with placebo at 30 weeks. Both doses lie outside the strict below-0.5 mg registration; the trial does not isolate microdose efficacy in the specified obesity population.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 23 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C24", "text": "SUSTAIN 2 found 4.3/6.1 kg loss with weekly 0.5/1 mg versus 1.9 kg with sitagliptin at 56 weeks, with more adverse-event discontinuation. Excluded doses and an active comparator cannot establish microdose noninferiority to 2.4 mg or fewer harms.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 24 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C25", "text": "SUSTAIN 4 found weight loss with weekly 0.5/1 mg versus weight gain with glargine at 30 weeks, with fewer hypoglycemic events. The open-label comparison, background drugs and excluded doses provide no direct microdose maintenance evidence.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 25 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C26", "text": "SUSTAIN 5 found 3.7/6.4 kg loss with weekly 0.5/1 mg versus 1.4 kg with placebo in basal-insulin-treated diabetes. No below-0.5 mg maintenance arm was randomized; diabetes and insulin context must remain explicit.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 26 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C27", "text": "SUSTAIN 3 found 5.6 kg loss with weekly 1 mg versus 1.9 kg with extended-release exenatide at 56 weeks, with more gastrointestinal events. Open-label approved-dose comparison does not establish microdose efficacy or equivalence to 2.4 mg.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 27 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C28", "text": "SUSTAIN 9 found 1 mg weekly added to SGLT2 therapy reduced weight beyond placebo; 0.25 mg was used only during four-week titration. Titration cannot be credited as maintenance; three parent-linked errata are recorded without inventing their unexamined contents.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 28 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C29", "text": "SUSTAIN 10 found 5.8 kg loss with weekly 1 mg versus 1.9 kg with daily liraglutide at 30 weeks, with more gastrointestinal discontinuation. No microdose arm; malformed inequality glyphs in the indexed abstract are not reproduced as precise threshold claims.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 29 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C30", "text": "SUSTAIN FORTE found a 2-versus-1 mg weight advantage significant under the trial-product estimand but not under treatment policy at 40 weeks. Both doses are excluded; estimand-dependent superiority cannot establish microdose noninferiority or lower harm.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 30 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C31", "text": "SUSTAIN 8 DXA results showed lean mass decreased despite increased lean proportion, with nonsignificant semaglutide-versus-canagliflozin differences. Only 114 of 178 had end-treatment data; no placebo, strength or function measurement establishes muscle dysfunction or protection.", "carries_number": true, "load_bearing_for": [ "SC5" ], "source_ns": [ 31 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C32", "text": "STEP 4 randomized 803 participants tolerating 2.4 mg after run-in; continuation caused further loss whereas withdrawal caused regain over 48 weeks. Selection after tolerability and a 2.4 mg regimen do not establish below-0.5 mg microdose maintenance efficacy.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3", "SC5" ], "source_ns": [ 32 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C33", "text": "The exploratory STEP 1 extension found regain of roughly two-thirds of prior weight loss after drug and lifestyle support stopped. Selected completers, shared parent data and simultaneous withdrawal of lifestyle support limit independent inference; no microdose arm.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 33 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C34", "text": "STEP 2 randomized adults with diabetes to 2.4 mg, 1 mg or placebo; 2.4 mg caused 9.6% versus 3.4% loss at 68 weeks. The dose comparison does not contain a below-0.5 mg arm; positive higher-dose effects cannot cross its registered threshold.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 34 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C35", "text": "STEP 3 found 16.0% versus 5.7% weight loss with 2.4 mg versus placebo alongside matched intensive behavioral support. A matched diet and counseling bundle does not isolate titration-dose maintenance or justify a microdose claim.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 35 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C36", "text": "STEP 8 found 15.8% loss with weekly 2.4 mg versus 6.4% with daily liraglutide at 68 weeks. Active comparisons were open-label with different titration/tolerability options; no microdose noninferiority was tested.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 36 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C37", "text": "STEP 5 found sustained 15.2% versus 2.6% loss with weekly 2.4 mg versus placebo at 104 weeks. The high dose and longer horizon provide genuine comparator efficacy but not the registered microdose result.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 37 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C38", "text": "The STEP 5 eating-control subset showed sustained improvements in some craving domains correlated with weight loss; hunger/fullness effects were early. Subset selection, multiplicity and correlation cannot show necessary mediation by a validated food-noise construct; this shares STEP 5 participants.", "carries_number": true, "load_bearing_for": [ "SC4" ], "source_ns": [ 38 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C39", "text": "SELECT found fewer major cardiovascular events with 2.4 mg than placebo in 17,604 adults with cardiovascular disease and no diabetes, with more discontinuation. Hard clinical benefit at the tested dose does not establish comparable microdose benefit-harm or dose-specific noninferiority.", "carries_number": true, "load_bearing_for": [ "SC3" ], "source_ns": [ 39 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C40", "text": "SELECT anthropometric analysis found sustained 10.2% versus 1.5% weight loss at 208 weeks across baseline BMI strata. Shared SELECT participants and flexible dose histories do not supply randomized below-0.5 mg maintenance evidence.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 40 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C41", "text": "SELECT safety analysis found fewer serious events but more gastrointestinal discontinuation and gallbladder disorders with semaglutide. Endpoint-specific benefit-harm and shared trial data cannot demonstrate a microdose safety advantage.", "carries_number": false, "load_bearing_for": [ "SC3" ], "source_ns": [ 41 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C42", "text": "SUSTAIN 6 found fewer pooled major cardiovascular events but more retinopathy complications with weekly 0.5/1 mg in high-risk diabetes. Both doses are excluded; pooled dose effects and noninferiority design cannot establish microdose hard outcomes or a uniformly safer profile.", "carries_number": true, "load_bearing_for": [ "SC3" ], "source_ns": [ 42 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C43", "text": "FLOW found fewer major kidney-composite events with weekly 1 mg versus placebo over 3.4 years in diabetes and kidney disease. The dose, kidney-defined population and long horizon are specific; genuine benefit cannot be inherited by microdose claims.", "carries_number": true, "load_bearing_for": [ "SC3" ], "source_ns": [ 43 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C44", "text": "STEP-HFpEF found 2.4 mg improved six-minute walking and symptom/physical-limitations scores beyond placebo in obesity-related heart failure. Exercise improvement is real but does not isolate muscle preservation or test low-dose dysfunction prevention.", "carries_number": true, "load_bearing_for": [ "SC5" ], "source_ns": [ 44 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C45", "text": "STEP-HFpEF DM found 2.4 mg improved walking and symptom/physical-limitations scores in obesity-related heart failure and diabetes. Cardiorespiratory function is not isolated muscle strength; later analyses share this parent trial and contain no microdose arm.", "carries_number": true, "load_bearing_for": [ "SC5" ], "source_ns": [ 45 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C46", "text": "STEP 9 found 2.4 mg improved weight, knee pain and reported physical function more than placebo at 68 weeks. Osteoarthritis symptom relief is not proof of microdose muscle preservation or prevention of sarcopenia.", "carries_number": true, "load_bearing_for": [ "SC2", "SC5" ], "source_ns": [ 46 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C47", "text": "STEP 10 found 13.9% versus 2.7% weight loss with 2.4 mg versus placebo at 52 weeks in obesity and prediabetes. Clinical efficacy belongs to the tested standard-dose context; normoglycemia is not proof of comparable microdose hard outcomes.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 47 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C48", "text": "STEP 7 found 12.1% versus 3.6% loss with 2.4 mg versus placebo in predominantly East Asian adults at 44 weeks. Population replication of one pharmacological modality does not create direct microdose evidence or an independent causal line.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 48 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C49", "text": "STEP 11 found 16.0% versus 3.1% loss with 2.4 mg versus placebo at 44 weeks in Asian adults selected by BMI at least 25. Some enrollment lies outside the fixed obesity eligibility; whole-cohort effects cannot supply an exact-scope microdose estimate.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 49 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C50", "text": "A 30-person retrospective series observed maintained weight/body composition after reducing dosing frequency, usually to every other week, at the existing dose. Mixed agents, prior-plateau selection and no control do not test below-0.5 mg once-weekly maintenance against placebo; mass stabilization is not strength preservation.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3", "SC5" ], "source_ns": [ 50 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C51", "text": "SEMALEAN followed 115 adults prescribed 2.4 mg; 106 completers showed early lean loss followed by stabilization and improved grip strength. Uncontrolled completion and dose selection cannot prove microdose protection; lean loss and functional decline are distinct outcomes.", "carries_number": true, "load_bearing_for": [ "SC5" ], "source_ns": [ 51 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C52", "text": "A retrospective older-diabetes cohort associated semaglutide with mass and functional decline compared with matched controls over 24 months. Residual confounding, dose choice and comorbidity limit causality; the result does not show every dose causes harm or that microdosing prevents it.", "carries_number": true, "load_bearing_for": [ "SC5" ], "source_ns": [ 52 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C53", "text": "Obese mice lost muscle and fat with semaglutide; adding an ActRII antibody preserved lean mass and improved exercise performance. An added antibody and daily mouse exposure cannot establish human microdose protection; lean-mass correlation does not isolate function causally.", "carries_number": false, "load_bearing_for": [ "SC5" ], "source_ns": [ 53 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C54", "text": "Obese mice and myotubes showed less atrophy with liraglutide/semaglutide, with effects attenuated after SIRT1 inhibition. Single-strain and cell-inhibitor results have system and specificity limits and do not establish weekly human microdose protection.", "carries_number": true, "load_bearing_for": [ "SC5" ], "source_ns": [ 54 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C55", "text": "Pooled STEP analyses found similar weight loss with and without gastrointestinal events; statistical mediation estimated little nausea-related contribution. Postrandomization grouping is not mediator manipulation; nausea is not food noise, and pooled reports do not create microdose noninferiority.", "carries_number": false, "load_bearing_for": [ "SC3", "SC4" ], "source_ns": [ 55 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C56", "text": "Pooled STEP-HFpEF analyses found lower multidomain frailty burden with 2.4 mg and greater symptom benefit in the most frail baseline group. A frailty index is not isolated muscle strength; the two shared parent trials cannot establish microdose protection.", "carries_number": true, "load_bearing_for": [ "SC5" ], "source_ns": [ 56 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C57", "text": "A 24-person nine-week smoking trial found lower weight and nicotine craving despite null primary laboratory smoking interactions. 0.25 mg was only four-week titration before escalation; short exposure and nicotine craving cannot test food-noise necessity or weight maintenance.", "carries_number": true, "load_bearing_for": [ "SC1", "SC2", "SC4" ], "source_ns": [ 57 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C58", "text": "A 20-person PCOS cohort on metformin plus weekly 0.25-0.5 mg observed weight/fat loss and nonsignificant lean-mass change at five months. Pooled doses, metformin and no placebo prevent isolation of below-0.5 mg causality; the reported weight endpoint precedes 24 weeks and BIA is not function.", "carries_number": true, "load_bearing_for": [ "SC2", "SC5" ], "source_ns": [ 58 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C59", "text": "A 13-person dialysis cohort observed 4.6 kg mean loss over 12 weeks with escalation from 0.25 to 0.5 to 1 mg. Uncontrolled special-population exposure, short duration and mixed escalation do not test microdose maintenance.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 59 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C60", "text": "A federated EHR analysis identified 814 adults with at least three 0.25 mg-only semaglutide prescriptions spanning at least six months; mean 12-month weight change was -2.2% (versus -5.5% on sustained 2.5 mg tirzepatide). Observational, uncontrolled for placebo and selected by prescription pattern, it is the closest real-world record of sustained sub-0.5 mg weekly exposure and does not show clinically meaningful (at least 5%) loss.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 60 ], "verification": "verified", "verified_against": "Original primary abstract and linked-status metadata examined via PubMed on 2026-11-02 during the second adversarial review; no complete-abstract, complete-paper or supplement audit claimed.", "verified_on": "2026-11-02", "note": "Added in the 2026-11-02 adversarial review." }, { "id": "C61", "text": "A population pharmacokinetic and exposure-response model built on the daily 0.05-0.4 mg dose-ranging trial and two weekly 2.4 mg phase 3 trials found that systemic exposure over time consistently explained weight-loss trajectories across trials and dosing regimens. A sponsor model of exposure, not a randomized test of sustained sub-0.5 mg weekly maintenance; it makes the 0.05 mg daily arm the closest exposure-matched randomized evidence but does not override the preregistered exclusion of daily-to-weekly conversion.", "carries_number": true, "load_bearing_for": [ "SC1", "SC2" ], "source_ns": [ 61 ], "verification": "verified", "verified_against": "Original primary abstract and linked-status metadata examined via PubMed on 2026-11-02 during the second adversarial review; no complete-abstract, complete-paper or supplement audit claimed.", "verified_on": "2026-11-02", "note": "Added in the 2026-11-02 adversarial review." }, { "id": "CSC1", "text": "Weekly dose-finding included 0.1-0.8 mg without escalation over 12 weeks in diabetes, supporting exposure-response plausibility. Its examined abstract does not isolate low-arm appetite effects, and glycemic change alone is not a clinical phenotype crossing. The 1/2.4 mg and oral appetite experiments cannot establish sustained engagement of both registered pathways under the strict microdose maintenance exposure.", "carries_number": false, "load_bearing_for": [ "SC1" ], "source_ns": [ 1, 3, 5, 6, 7, 8, 22, 57 ], "verification": "verified", "verified_against": "Synthesis of examined primary result/limit cards; framework level is adjudication.", "verified_on": "2026-10-13", "note": "" }, { "id": "CSC2", "text": "No examined randomized original assigns strictly below 0.5 mg weekly maintenance versus placebo for at least 5% loss at 24-68 weeks in the registered BMI-defined population. Twelve-week weekly dose-finding is too short; daily dose-ranging has another schedule; 0.5/1/2.4 mg trials have another maintenance exposure. Small mixed-dose and cointervention cohorts provide partial support without a clean exact-scope causal perturbation. This is an evidence gap, not proof that microdosing cannot work. The largest on-exposure record, a federated EHR cohort of 814 adults on sustained 0.25 mg-only prescriptions (PMID 42857675), observed -2.2% mean 12-month weight change; being observational, without placebo and prescription-selected, it leans against the claim without supplying the missing placebo-controlled test.", "carries_number": false, "load_bearing_for": [ "SC2" ], "source_ns": [ 1, 2, 9, 10, 12, 13, 14, 15, 16, 22, 23, 24, 25, 26, 27, 28, 29, 30, 32, 33, 34, 35, 36, 37, 40, 46, 47, 48, 49, 50, 57, 58, 59, 60 ], "verification": "verified", "verified_against": "Synthesis of examined primary result/limit cards; framework level is adjudication.", "verified_on": "2026-10-13", "note": "" }, { "id": "CSC3", "text": "Comparable weight and clinical benefits to 2.4 mg plus fewer adverse effects is not established by a direct randomized noninferiority/benefit-harm contrast. Final-dose observational nulls are not equivalence tests. A lower-dose tolerability hypothesis has biological rationale but the full positive equivalence conjunction remains speculative; exact-dose clinical data are missing.", "carries_number": false, "load_bearing_for": [ "SC3" ], "source_ns": [ 1, 2, 4, 9, 10, 12, 13, 15, 16, 22, 23, 24, 25, 26, 27, 28, 29, 30, 32, 33, 34, 35, 36, 37, 39, 40, 41, 42, 43, 47, 48, 49, 50, 55, 59 ], "verification": "verified", "verified_against": "Synthesis of examined primary result/limit cards; framework level is adjudication.", "verified_on": "2026-10-13", "note": "" }, { "id": "CSC4", "text": "Randomized semaglutide experiments establish changes in intake, appetite and some reward measures; validated food-noise measurements in the examined semaglutide survey remain retrospective and descriptive. In a 60-week trial, measured intake differences persist at 20/40/60 weeks while hunger and food-preoccupation contrasts lose significance after week 20; food-reward responsiveness (Power of Food Scale), the measure closest to the food-noise construct, still differed at week 40, and only at week 60 did no subjective contrast remain. This narrows an obligatory subjective pathway but does not directly remove the validated construct. Necessary food-noise mediation remains partial-system plausibility, not a demonstrated dependency.", "carries_number": false, "load_bearing_for": [ "SC4" ], "source_ns": [ 3, 4, 5, 6, 7, 8, 17, 18, 19, 20, 21, 38, 55, 57 ], "verification": "verified", "verified_against": "Synthesis of examined primary result/limit cards; framework level is adjudication.", "verified_on": "2026-10-13", "note": "" }, { "id": "CSC5", "text": "Animal atrophy and co-treatment experiments plus mixed human functional observations support a possible muscle-related pathway. No direct human microdose comparison demonstrates prevention of clinically important strength or function loss. SEMALEAN grip improvement at 2.4 mg is uncontrolled; retrospective older-diabetes decline is confounded; MRI/DXA mass changes and relative lean proportion cannot substitute for function.", "carries_number": false, "load_bearing_for": [ "SC5" ], "source_ns": [ 4, 9, 10, 11, 13, 14, 20, 31, 32, 44, 45, 46, 50, 51, 52, 53, 54, 56, 58 ], "verification": "verified", "verified_against": "Synthesis of examined primary result/limit cards; framework level is adjudication.", "verified_on": "2026-10-13", "note": "" }, { "id": "CH", "text": "Semaglutide works at tested clinical doses; sustained weight-loss efficacy of weekly maintenance strictly below 0.5 mg remains unestablished in this review.", "carries_number": false, "load_bearing_for": [ "SC2" ], "source_ns": [ 22, 1, 9, 2, 58, 16 ], "verification": "verified", "verified_against": "Bounded synthesis of examined sources; score is adjudication.", "verified_on": "2026-10-13", "note": "" } ], "citation_ledger": [ { "n": 1, "citation": "O'Neil PM, Birkenfeld AL, McGowan B et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet (London, England). 2018.", "tier": "A", "kind": "rct", "pmid": "30122305", "doi": "10.1016/S0140-6736(18)31773-2", "url": "https://pubmed.ncbi.nlm.nih.gov/30122305/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID30122305", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C1", "CSC1", "CSC2", "CSC3", "CH" ] }, { "n": 2, "citation": "Pampanelli S, Terzoni S, Pantanetti P et al. Flexible dose of semaglutide reduces early discontinuation while maintaining comparable outcomes in obese patients: FLEX-SEMA 2.4 mg, an Italian real-world study. Diabetes, obesity & metabolism. 2026.", "tier": "A", "kind": "primary", "pmid": "41725422", "doi": "10.1111/dom.70538", "url": "https://pubmed.ncbi.nlm.nih.gov/41725422/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID41725422", "access_depth": "full_text_partial", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:MATERIALS AND METHODS:paragraph0, 1:MATERIALS AND METHODS:paragraph1, 1:MATERIALS AND METHODS:paragraph7, 1:MATERIALS AND METHODS:paragraph8, 2:RESULTS:paragraph1, 2:RESULTS:paragraph3, 2:RESULTS:paragraph14, 2:RESULTS:paragraph15, 2:RESULTS:paragraph16, 2:RESULTS:paragraph19. No complete-paper or supplement audit claimed.", "carries_claims": [ "C2", "CSC2", "CSC3", "CH" ] }, { "n": 3, "citation": "Blundell J, Finlayson G, Axelsen M et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes, obesity & metabolism. 2017.", "tier": "A", "kind": "rct", "pmid": "28266779", "doi": "10.1111/dom.12932", "url": "https://pubmed.ncbi.nlm.nih.gov/28266779/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID28266779", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C3", "CSC1", "CSC4" ] }, { "n": 4, "citation": "Heise T, DeVries JH, Urva S et al. Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes. Diabetes care. 2023.", "tier": "A", "kind": "rct", "pmid": "36857477", "doi": "10.2337/dc22-1710", "url": "https://pubmed.ncbi.nlm.nih.gov/36857477/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID36857477", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C4", "CSC3", "CSC4", "CSC5" ] }, { "n": 5, "citation": "Friedrichsen M, Breitschaft A, Tadayon S et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes, obesity & metabolism. 2021.", "tier": "A", "kind": "rct", "pmid": "33269530", "doi": "10.1111/dom.14280", "url": "https://pubmed.ncbi.nlm.nih.gov/33269530/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID33269530", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C5", "CSC1", "CSC4" ] }, { "n": 6, "citation": "Gabe MBN, Breitschaft A, Knop FK et al. Effect of oral semaglutide on energy intake, appetite, control of eating and gastric emptying in adults living with obesity: A randomized controlled trial. Diabetes, obesity & metabolism. 2024.", "tier": "A", "kind": "rct", "pmid": "39082206", "doi": "10.1111/dom.15802", "url": "https://pubmed.ncbi.nlm.nih.gov/39082206/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID39082206", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C6", "CSC1", "CSC4" ] }, { "n": 7, "citation": "Gibbons C, Blundell J, Tetens Hoff S et al. Effects of oral semaglutide on energy intake, food preference, appetite, control of eating and body weight in subjects with type 2 diabetes. Diabetes, obesity & metabolism. 2021.", "tier": "A", "kind": "rct", "pmid": "33184979", "doi": "10.1111/dom.14255", "url": "https://pubmed.ncbi.nlm.nih.gov/33184979/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID33184979", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C7", "CSC1", "CSC4" ] }, { "n": 8, "citation": "Tronieri JS, Allison KC, DeRouen K et al. Short- and long-term effects of semaglutide 2.4 mg on energy intake, appetite, and food reward: a 60-week, double-blind randomized controlled trial. The American journal of clinical nutrition. 2026.", "tier": "A", "kind": "rct", "pmid": "42323166", "doi": "10.1016/j.ajcnut.2026.101403", "url": "https://pubmed.ncbi.nlm.nih.gov/42323166/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "NCT05548647", "access_depth": "full_text_partial", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Methods:paragraph0, 1:Methods:paragraph1, 1:Methods:paragraph3, 1:Methods:paragraph4, 1:Methods:paragraph8, 1:Methods:paragraph12, 2:Results:paragraph8, 2:Results:paragraph10, 2:Results:paragraph19, 2:Results:paragraph21, 2:Results:paragraph22. No complete-paper or supplement audit claimed.", "carries_claims": [ "C8", "CSC1", "CSC4" ] }, { "n": 9, "citation": "Wilding JPH, Batterham RL, Calanna S et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England journal of medicine. 2021.", "tier": "A", "kind": "rct", "pmid": "33567185", "doi": "10.1056/NEJMoa2032183", "url": "https://pubmed.ncbi.nlm.nih.gov/33567185/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "STEP1-NCT03548935", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C9", "CSC2", "CSC3", "CSC5", "CH" ] }, { "n": 10, "citation": "Kadowaki T, Isendahl J, Khalid U et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. The lancet. Diabetes & endocrinology. 2022.", "tier": "A", "kind": "rct", "pmid": "35131037", "doi": "10.1016/S2213-8587(22)00008-0", "url": "https://pubmed.ncbi.nlm.nih.gov/35131037/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID35131037", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C10", "CSC2", "CSC3", "CSC5" ] }, { "n": 11, "citation": "Hjelmesæth J, Bhat S, Garvey WT et al. Effect of Semaglutide on Thigh Skeletal Muscle Volume, Fat Infiltration and Physical Function in People With Obesity: Secondary Analysis of STEP UP. Diabetes, obesity & metabolism. 2026.", "tier": "A", "kind": "primary", "pmid": "42764399", "doi": "10.1111/dom.71323", "url": "https://pubmed.ncbi.nlm.nih.gov/42764399/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "STEPUP-NCT05646706", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C11", "CSC5" ] }, { "n": 12, "citation": "Pratley RE, Aroda VR, Lingvay I et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. The lancet. Diabetes & endocrinology. 2018.", "tier": "A", "kind": "rct", "pmid": "29397376", "doi": "10.1016/S2213-8587(18)30024-X", "url": "https://pubmed.ncbi.nlm.nih.gov/29397376/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID29397376", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C12", "CSC2", "CSC3" ] }, { "n": 13, "citation": "Lingvay I, Bergenheim SJ, Buse JB et al. Once-weekly semaglutide 7·2 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trial. The lancet. Diabetes & endocrinology. 2025.", "tier": "A", "kind": "rct", "pmid": "40961953", "doi": "10.1016/S2213-8587(25)00225-6", "url": "https://pubmed.ncbi.nlm.nih.gov/40961953/", "status_flags": [ "ErratumIn: PMID41932351" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID40961953", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C13", "CSC2", "CSC3", "CSC5" ] }, { "n": 14, "citation": "Davies MJ, van der Meer P, Verma S et al. Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA1c levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial. The lancet. Diabetes & endocrinology. 2025.", "tier": "A", "kind": "rct", "pmid": "39848268", "doi": "10.1016/S2213-8587(24)00304-8", "url": "https://pubmed.ncbi.nlm.nih.gov/39848268/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "STEP-HFpEF-DM-NCT04916470", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C14", "CSC2", "CSC5" ] }, { "n": 15, "citation": "Mulvagh SL, Inzucchi SE, Marx N et al. Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes: A Post Hoc Secondary Analysis of the SOUL Randomized Clinical Trial. JAMA cardiology. 2026.", "tier": "A", "kind": "rct", "pmid": "41879791", "doi": "10.1001/jamacardio.2026.0245", "url": "https://pubmed.ncbi.nlm.nih.gov/41879791/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID41879791", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C15", "CSC2", "CSC3" ] }, { "n": 16, "citation": "Tzoulis P, Batavanis M, Baldeweg S. A Real-World Study of the Effectiveness and Safety of Semaglutide for Weight Loss. Cureus. 2024.", "tier": "A", "kind": "primary", "pmid": "38826889", "doi": "10.7759/cureus.59558", "url": "https://pubmed.ncbi.nlm.nih.gov/38826889/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID38826889", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C16", "CSC2", "CSC3", "CH" ] }, { "n": 17, "citation": "de Vere Hunt I, Ramirez-Posada M, Babu CS et al. Patient Experiences With GLP-1 Receptor Agonists. JAMA network open. 2026.", "tier": "A", "kind": "primary", "pmid": "42247231", "doi": "10.1001/jamanetworkopen.2026.16951", "url": "https://pubmed.ncbi.nlm.nih.gov/42247231/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID42247231", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C17", "CSC4" ] }, { "n": 18, "citation": "Naveed M, Perez C, Ahmad E et al. GLP-1 medication and weight loss: Barriers and motivators among 1659 participants managed in a virtual setting. Diabetes, obesity & metabolism. 2025.", "tier": "A", "kind": "primary", "pmid": "40259493", "doi": "10.1111/dom.16405", "url": "https://pubmed.ncbi.nlm.nih.gov/40259493/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID40259493", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C18", "CSC4" ] }, { "n": 19, "citation": "Arnaut T, Duncan S, Faurby M et al. Retrospective Assessment of Food Noise Changes After Initiation of Injectable Semaglutide for Weight Management in the USA: The INFORM Survey. Advances in therapy. 2026.", "tier": "A", "kind": "primary", "pmid": "42217114", "doi": "10.1007/s12325-026-03636-x", "url": "https://pubmed.ncbi.nlm.nih.gov/42217114/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID42217114", "access_depth": "full_text_partial", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 2:Methods:paragraph1, 2:Methods:paragraph3, 2:Methods:paragraph4, 2:Methods:paragraph5, 2:Methods:paragraph11, 2:Methods:paragraph13, 3:Results:paragraph0, 3:Results:paragraph1, 3:Results:paragraph4. No complete-paper or supplement audit claimed.", "carries_claims": [ "C19", "CSC4" ] }, { "n": 20, "citation": "Rutigliani G, Mattes RD. The effects of glucagon-like peptide-1 receptor agonists on chemosensory function and ingestive behavior. Physiology & behavior. 2026.", "tier": "A", "kind": "primary", "pmid": "42641845", "doi": "10.1016/j.physbeh.2026.115486", "url": "https://pubmed.ncbi.nlm.nih.gov/42641845/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID42641845", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C20", "CSC4", "CSC5" ] }, { "n": 21, "citation": "Hayashi D, Kort J, Robles-Martinez IM et al. \"And just like that, quiet\": a content analysis of TikTok videos on food noise. Nutrition & diabetes. 2026.", "tier": "A", "kind": "primary", "pmid": "42049707", "doi": "10.1038/s41387-026-00423-z", "url": "https://pubmed.ncbi.nlm.nih.gov/42049707/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID42049707", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C21", "CSC4" ] }, { "n": 22, "citation": "Nauck MA, Petrie JR, Sesti G et al. A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes. Diabetes care. 2016.", "tier": "A", "kind": "rct", "pmid": "26358288", "doi": "10.2337/dc15-0165", "url": "https://pubmed.ncbi.nlm.nih.gov/26358288/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "WEEKLY-SEMA-PHASE2-12W", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C22", "CSC1", "CSC2", "CSC3", "CH" ] }, { "n": 23, "citation": "Sorli C, Harashima SI, Tsoukas GM et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. The lancet. Diabetes & endocrinology. 2017.", "tier": "A", "kind": "rct", "pmid": "28110911", "doi": "10.1016/S2213-8587(17)30013-X", "url": "https://pubmed.ncbi.nlm.nih.gov/28110911/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID28110911", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C23", "CSC2", "CSC3" ] }, { "n": 24, "citation": "Ahrén B, Masmiquel L, Kumar H et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. The lancet. Diabetes & endocrinology. 2017.", "tier": "A", "kind": "rct", "pmid": "28385659", "doi": "10.1016/S2213-8587(17)30092-X", "url": "https://pubmed.ncbi.nlm.nih.gov/28385659/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID28385659", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C24", "CSC2", "CSC3" ] }, { "n": 25, "citation": "Aroda VR, Bain SC, Cariou B et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. The lancet. Diabetes & endocrinology. 2017.", "tier": "A", "kind": "rct", "pmid": "28344112", "doi": "10.1016/S2213-8587(17)30085-2", "url": "https://pubmed.ncbi.nlm.nih.gov/28344112/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID28344112", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C25", "CSC2", "CSC3" ] }, { "n": 26, "citation": "Rodbard HW, Lingvay I, Reed J et al. Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial. The Journal of clinical endocrinology and metabolism. 2018.", "tier": "A", "kind": "rct", "pmid": "29688502", "doi": "10.1210/jc.2018-00070", "url": "https://pubmed.ncbi.nlm.nih.gov/29688502/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID29688502", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C26", "CSC2", "CSC3" ] }, { "n": 27, "citation": "Ahmann AJ, Capehorn M, Charpentier G et al. Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial. Diabetes care. 2018.", "tier": "A", "kind": "rct", "pmid": "29246950", "doi": "10.2337/dc17-0417", "url": "https://pubmed.ncbi.nlm.nih.gov/29246950/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID29246950", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C27", "CSC2", "CSC3" ] }, { "n": 28, "citation": "Zinman B, Bhosekar V, Busch R et al. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial. The lancet. Diabetes & endocrinology. 2019.", "tier": "A", "kind": "rct", "pmid": "30833170", "doi": "10.1016/S2213-8587(19)30066-X", "url": "https://pubmed.ncbi.nlm.nih.gov/30833170/", "status_flags": [ "ErratumIn: PMID30872122", "ErratumIn: PMID31272930", "ErratumIn: PMID31621596" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID30833170", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C28", "CSC2", "CSC3" ] }, { "n": 29, "citation": "Capehorn MS, Catarig AM, Furberg JK et al. Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes & metabolism. 2020.", "tier": "A", "kind": "rct", "pmid": "31539622", "doi": "10.1016/j.diabet.2019.101117", "url": "https://pubmed.ncbi.nlm.nih.gov/31539622/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID31539622", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C29", "CSC2", "CSC3" ] }, { "n": 30, "citation": "Frías JP, Auerbach P, Bajaj HS et al. Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial. The lancet. Diabetes & endocrinology. 2021.", "tier": "A", "kind": "rct", "pmid": "34293304", "doi": "10.1016/S2213-8587(21)00174-1", "url": "https://pubmed.ncbi.nlm.nih.gov/34293304/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID34293304", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C30", "CSC2", "CSC3" ] }, { "n": 31, "citation": "McCrimmon RJ, Catarig AM, Frias JP et al. Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial. Diabetologia. 2020.", "tier": "A", "kind": "rct", "pmid": "31897524", "doi": "10.1007/s00125-019-05065-8", "url": "https://pubmed.ncbi.nlm.nih.gov/31897524/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "SUSTAIN8-NCT03136484", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C31", "CSC5" ] }, { "n": 32, "citation": "Rubino D, Abrahamsson N, Davies M et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.", "tier": "A", "kind": "rct", "pmid": "33755728", "doi": "10.1001/jama.2021.3224", "url": "https://pubmed.ncbi.nlm.nih.gov/33755728/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "STEP4-NCT03548987", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C32", "CSC2", "CSC3", "CSC5" ] }, { "n": 33, "citation": "Wilding JPH, Batterham RL, Davies M et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, obesity & metabolism. 2022.", "tier": "A", "kind": "rct", "pmid": "35441470", "doi": "10.1111/dom.14725", "url": "https://pubmed.ncbi.nlm.nih.gov/35441470/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "STEP1-NCT03548935", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C33", "CSC2", "CSC3" ] }, { "n": 34, "citation": "Davies M, Færch L, Jeppesen OK et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet (London, England). 2021.", "tier": "A", "kind": "rct", "pmid": "33667417", "doi": "10.1016/S0140-6736(21)00213-0", "url": "https://pubmed.ncbi.nlm.nih.gov/33667417/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "STEP2-NCT03552757", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C34", "CSC2", "CSC3" ] }, { "n": 35, "citation": "Wadden TA, Bailey TS, Billings LK et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021.", "tier": "A", "kind": "rct", "pmid": "33625476", "doi": "10.1001/jama.2021.1831", "url": "https://pubmed.ncbi.nlm.nih.gov/33625476/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "STEP3-NCT03611582", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C35", "CSC2", "CSC3" ] }, { "n": 36, "citation": "Rubino DM, Greenway FL, Khalid U et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022.", "tier": "A", "kind": "rct", "pmid": "35015037", "doi": "10.1001/jama.2021.23619", "url": "https://pubmed.ncbi.nlm.nih.gov/35015037/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID35015037", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C36", "CSC2", "CSC3" ] }, { "n": 37, "citation": "Garvey WT, Batterham RL, Bhatta M et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature medicine. 2022.", "tier": "A", "kind": "rct", "pmid": "36216945", "doi": "10.1038/s41591-022-02026-4", "url": "https://pubmed.ncbi.nlm.nih.gov/36216945/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "STEP5-NCT03693430", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C37", "CSC2", "CSC3" ] }, { "n": 38, "citation": "Wharton S, Batterham RL, Bhatta M et al. Two-year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5. Obesity (Silver Spring, Md.). 2023.", "tier": "A", "kind": "rct", "pmid": "36655300", "doi": "10.1002/oby.23673", "url": "https://pubmed.ncbi.nlm.nih.gov/36655300/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "STEP5-NCT03693430", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C38", "CSC4" ] }, { "n": 39, "citation": "Lincoff AM, Brown-Frandsen K, Colhoun HM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. The New England journal of medicine. 2023.", "tier": "A", "kind": "rct", "pmid": "37952131", "doi": "10.1056/NEJMoa2307563", "url": "https://pubmed.ncbi.nlm.nih.gov/37952131/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "SELECT-NCT03574597", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C39", "CSC3" ] }, { "n": 40, "citation": "Ryan DH, Lingvay I, Deanfield J et al. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nature medicine. 2024.", "tier": "A", "kind": "rct", "pmid": "38740993", "doi": "10.1038/s41591-024-02996-7", "url": "https://pubmed.ncbi.nlm.nih.gov/38740993/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "SELECT-NCT03574597", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C40", "CSC2", "CSC3" ] }, { "n": 41, "citation": "Kushner RF, Ryan DH, Deanfield J et al. Safety profile of semaglutide versus placebo in the SELECT study: a randomized controlled trial. Obesity (Silver Spring, Md.). 2025.", "tier": "A", "kind": "rct", "pmid": "39948761", "doi": "10.1002/oby.24222", "url": "https://pubmed.ncbi.nlm.nih.gov/39948761/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "SELECT-NCT03574597", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C41", "CSC3" ] }, { "n": 42, "citation": "Marso SP, Bain SC, Consoli A et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. The New England journal of medicine. 2016.", "tier": "A", "kind": "rct", "pmid": "27633186", "doi": "10.1056/NEJMoa1607141", "url": "https://pubmed.ncbi.nlm.nih.gov/27633186/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "SUSTAIN6-NCT01720446", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C42", "CSC3" ] }, { "n": 43, "citation": "Perkovic V, Tuttle KR, Rossing P et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. The New England journal of medicine. 2024.", "tier": "A", "kind": "rct", "pmid": "38785209", "doi": "10.1056/NEJMoa2403347", "url": "https://pubmed.ncbi.nlm.nih.gov/38785209/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "FLOW-NCT03819153", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C43", "CSC3" ] }, { "n": 44, "citation": "Kosiborod MN, Abildstrøm SZ, Borlaug BA et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. The New England journal of medicine. 2023.", "tier": "A", "kind": "rct", "pmid": "37622681", "doi": "10.1056/NEJMoa2306963", "url": "https://pubmed.ncbi.nlm.nih.gov/37622681/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "STEP-HFpEF-NCT04788511", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C44", "CSC5" ] }, { "n": 45, "citation": "Kosiborod MN, Petrie MC, Borlaug BA et al. Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes. The New England journal of medicine. 2024.", "tier": "A", "kind": "rct", "pmid": "38587233", "doi": "10.1056/NEJMoa2313917", "url": "https://pubmed.ncbi.nlm.nih.gov/38587233/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "STEP-HFpEF-DM-NCT04916470", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C45", "CSC5" ] }, { "n": 46, "citation": "Bliddal H, Bays H, Czernichow S et al. Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis. The New England journal of medicine. 2024.", "tier": "A", "kind": "rct", "pmid": "39476339", "doi": "10.1056/NEJMoa2403664", "url": "https://pubmed.ncbi.nlm.nih.gov/39476339/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID39476339", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C46", "CSC2", "CSC5" ] }, { "n": 47, "citation": "McGowan BM, Bruun JM, Capehorn M et al. Efficacy and safety of once-weekly semaglutide 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial. The lancet. Diabetes & endocrinology. 2024.", "tier": "A", "kind": "rct", "pmid": "39089293", "doi": "10.1016/S2213-8587(24)00182-7", "url": "https://pubmed.ncbi.nlm.nih.gov/39089293/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID39089293", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C47", "CSC2", "CSC3" ] }, { "n": 48, "citation": "Mu Y, Bao X, Eliaschewitz FG et al. Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial. The lancet. Diabetes & endocrinology. 2024.", "tier": "A", "kind": "rct", "pmid": "38330988", "doi": "10.1016/S2213-8587(23)00388-1", "url": "https://pubmed.ncbi.nlm.nih.gov/38330988/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID38330988", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C48", "CSC2", "CSC3" ] }, { "n": 49, "citation": "Lim S, Buranapin S, Bao X et al. Once-weekly semaglutide 2·4 mg in an Asian population with obesity, defined as BMI ≥25 kg/m2, in South Korea and Thailand (STEP 11): a randomised, double-blind, placebo-controlled, phase 3 trial. The lancet. Diabetes & endocrinology. 2025.", "tier": "A", "kind": "rct", "pmid": "40825340", "doi": "10.1016/S2213-8587(25)00164-0", "url": "https://pubmed.ncbi.nlm.nih.gov/40825340/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID40825340", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C49", "CSC2", "CSC3" ] }, { "n": 50, "citation": "Wong M, Wu A, Garhe PK et al. Reduced-Frequency GLP1 Therapy Maintains Weight, Body Composition, and Metabolic Syndrome Improvements: A Case Series. Obesity (Silver Spring, Md.). 2026.", "tier": "A", "kind": "primary", "pmid": "41732031", "doi": "10.1002/oby.70137", "url": "https://pubmed.ncbi.nlm.nih.gov/41732031/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID41732031", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C50", "CSC2", "CSC3", "CSC5" ] }, { "n": 51, "citation": "Alissou M, Demangeat T, Folope V et al. Impact of Semaglutide on fat mass, lean mass and muscle function in patients with obesity: The SEMALEAN study. Diabetes, obesity & metabolism. 2026.", "tier": "A", "kind": "primary", "pmid": "41068996", "doi": "10.1111/dom.70141", "url": "https://pubmed.ncbi.nlm.nih.gov/41068996/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID41068996", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C51", "CSC5" ] }, { "n": 52, "citation": "Ren Q, Zhi L, Liu H. Semaglutide Therapy and Accelerated Sarcopenia in Older Adults with Type 2 Diabetes: A 24-Month Retrospective Cohort Study. Drug design, development and therapy. 2025.", "tier": "A", "kind": "primary", "pmid": "40631351", "doi": "10.2147/DDDT.S531778", "url": "https://pubmed.ncbi.nlm.nih.gov/40631351/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID40631351", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C52", "CSC5" ] }, { "n": 53, "citation": "Nunn E, Jaiswal N, Gavin M et al. Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism. Molecular metabolism. 2024.", "tier": "A", "kind": "primary", "pmid": "38218536", "doi": "10.1016/j.molmet.2024.101880", "url": "https://pubmed.ncbi.nlm.nih.gov/38218536/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID38218536", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C53", "CSC5" ] }, { "n": 54, "citation": "Xiang J, Qin L, Zhong J et al. GLP-1RA Liraglutide and Semaglutide Improves Obesity-Induced Muscle Atrophy via SIRT1 Pathway. Diabetes, metabolic syndrome and obesity : targets and therapy. 2023.", "tier": "A", "kind": "primary", "pmid": "37602204", "doi": "10.2147/DMSO.S425642", "url": "https://pubmed.ncbi.nlm.nih.gov/37602204/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID37602204", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C54", "CSC5" ] }, { "n": 55, "citation": "Wharton S, Calanna S, Davies M et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes, obesity & metabolism. 2022.", "tier": "A", "kind": "rct", "pmid": "34514682", "doi": "10.1111/dom.14551", "url": "https://pubmed.ncbi.nlm.nih.gov/34514682/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "STEP1-2-3-4-POOLED", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C55", "CSC3", "CSC4" ] }, { "n": 56, "citation": "Pandey A, Kitzman DW, Chinnakondepalli KM et al. Frailty and Effects of Semaglutide in Obesity-Related HFpEF: Findings From the STEP-HFpEF Program. JACC. Heart failure. 2025.", "tier": "A", "kind": "rct", "pmid": "40956259", "doi": "10.1016/j.jchf.2025.102610", "url": "https://pubmed.ncbi.nlm.nih.gov/40956259/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "STEP-HFpEF-POOLED", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C56", "CSC5" ] }, { "n": 57, "citation": "Hendershot CS, Bremmer MP, Paladino MB et al. Once-Weekly Semaglutide in Adults With Daily Cigarette Use: A Randomized Clinical Trial. JAMA network open. 2026.", "tier": "A", "kind": "rct", "pmid": "42189538", "doi": "10.1001/jamanetworkopen.2026.14898", "url": "https://pubmed.ncbi.nlm.nih.gov/42189538/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID42189538", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C57", "CSC1", "CSC2", "CSC4" ] }, { "n": 58, "citation": "Bolek T, Turňová P, Janošova S et al. Effect of semaglutide with metformin for weight loss and fertility in polycystic ovary syndrome (PCOS) patients with obesity: A pilot prospective study. Clinical nutrition ESPEN. 2026.", "tier": "A", "kind": "primary", "pmid": "41421448", "doi": "10.1016/j.clnesp.2025.102885", "url": "https://pubmed.ncbi.nlm.nih.gov/41421448/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID41421448", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C58", "CSC2", "CSC5", "CH" ] }, { "n": 59, "citation": "Vanek L, Kurnikowski A, Krenn S et al. Semaglutide in patients with kidney failure and obesity undergoing dialysis and wishing to be transplanted: A prospective, observational, open-label study. Diabetes, obesity & metabolism. 2024.", "tier": "A", "kind": "primary", "pmid": "39375862", "doi": "10.1111/dom.15967", "url": "https://pubmed.ncbi.nlm.nih.gov/39375862/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID39375862", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C59", "CSC2", "CSC3" ] }, { "n": 60, "citation": "Murugadoss K, Venkatakrishnan AJ, Soundararajan V. Comparison of cardiometabolic benefits and tolerability in patients on sustained low doses of semaglutide or tirzepatide. Biology methods & protocols. 2026.", "tier": "A", "kind": "primary", "pmid": "42857675", "doi": "10.1093/biomethods/bpag048", "url": "https://pubmed.ncbi.nlm.nih.gov/42857675/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-11-02", "status_checked_on": "2026-11-02", "study_id": "PMID42857675", "access_depth": "abstract_metadata", "access_note": "Original primary abstract and linked-status metadata examined via PubMed on 2026-11-02 during the second adversarial review; no complete-abstract, complete-paper or supplement audit claimed.", "carries_claims": [ "C60", "CSC2" ] }, { "n": 61, "citation": "Strathe A, Horn DB, Larsen MS et al. A model-based approach to predict individual weight loss with semaglutide in people with overweight or obesity. Diabetes, obesity & metabolism. 2023.", "tier": "A", "kind": "primary", "pmid": "37424165", "doi": "10.1111/dom.15211", "url": "https://pubmed.ncbi.nlm.nih.gov/37424165/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-11-02", "status_checked_on": "2026-11-02", "study_id": "PMID37424165", "access_depth": "abstract_metadata", "access_note": "Original primary abstract and linked-status metadata examined via PubMed on 2026-11-02 during the second adversarial review; no complete-abstract, complete-paper or supplement audit claimed.", "carries_claims": [ "C61" ] } ], "independence_basis": { "required": false, "lines": [], "shared_failure_mode_checked": true, "note": "No assigned subclaim or competing model reaches Ζ. STEP/SUSTAIN repetitions improve clinical confidence without automatically adding independent causal lines. Parent trial reports and pooled analyses share participants; different doses/sponsors alone do not pass the shared-failure test." }, "gamma_hard_rules_considered": [ { "subclaim_id": "SC1", "rule_quoted": "ROS change measurements alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC1", "rule_quoted": "NAD level change measurements alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC1", "rule_quoted": "Mitochondrial metrics alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC1", "rule_quoted": "Senescence marker changes alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC1", "rule_quoted": "Single-species or single-strain evidence", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC1", "rule_quoted": "Biomarker-only improvement without organismal benefit", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC2", "rule_quoted": "ROS change measurements alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC2", "rule_quoted": "NAD level change measurements alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC2", "rule_quoted": "Mitochondrial metrics alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC2", "rule_quoted": "Senescence marker changes alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC2", "rule_quoted": "Single-species or single-strain evidence", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC2", "rule_quoted": "Biomarker-only improvement without organismal benefit", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC3", "rule_quoted": "ROS change measurements alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC3", "rule_quoted": "NAD level change measurements alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC3", "rule_quoted": "Mitochondrial metrics alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC3", "rule_quoted": "Senescence marker changes alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC3", "rule_quoted": "Single-species or single-strain evidence", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC3", "rule_quoted": "Biomarker-only improvement without organismal benefit", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC4", "rule_quoted": "ROS change measurements alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC4", "rule_quoted": "NAD level change measurements alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC4", "rule_quoted": "Mitochondrial metrics alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC4", "rule_quoted": "Senescence marker changes alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC4", "rule_quoted": "Single-species or single-strain evidence", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC4", "rule_quoted": "Biomarker-only improvement without organismal benefit", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC5", "rule_quoted": "ROS change measurements alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC5", "rule_quoted": "NAD level change measurements alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC5", "rule_quoted": "Mitochondrial metrics alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC5", "rule_quoted": "Senescence marker changes alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC5", "rule_quoted": "Single-species or single-strain evidence", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC5", "rule_quoted": "Biomarker-only improvement without organismal benefit", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." } ], "consensus_validation": { "completed": true, "status": "completed_original_source_reconciliation", "provider_mode": "Authenticated Consensus Deep research connector; completed provider output retained privately; original-source access checked separately", "queries": [ "https://consensus.app/search/for-an-exhaustive-primary-literature-review-suppor/VpbkCn0iRIG1gtRae9Cv0w/" ], "query_record_note": "Exact provider question/response retained privately in its retrieval receipt.", "primary_comparison_count": 10, "primary_comparisons": [ { "pmid": "33567185", "doi": "10.1056/NEJMoa2032183", "source_type": "primary study report", "study_group": "STEP 1-NCT03548935", "access_depth": "abstract_metadata", "consensus_aspect": "Standard-dose efficacy versus exact microdose scope", "result_comparison": "Consensus separates the 2.4 mg STEP 1 trial from strict below-0.5 mg maintenance. The examined original confirms 1,961 adults, BMI-defined enrollment, 68 weeks and 14.9% versus 2.4% mean loss. Its 86.4% versus 31.5% at least-5% responder result belongs to 2.4 mg, not the titration step.", "original_source": "https://pubmed.ncbi.nlm.nih.gov/33567185/", "source_examination_receipts": [ "deliverables\\hsef_v53_traffic_ranks_06_10_2026-10-13\\glp 1-microdosing\\examinations\\original-8-16-10000.json" ], "body_receipts": [] }, { "pmid": "26358288", "doi": "10.2337/dc15-0165", "source_type": "primary study report", "study_group": "WEEKLY-SEMA-PHASE2-12W", "access_depth": "abstract_metadata", "consensus_aspect": "Short weekly dose-finding does not establish long maintenance", "result_comparison": "Consensus identifies the early weekly phase 2 trial as 12-week boundary evidence. The examined original abstract confirms weekly 0.1-0.8 mg without escalation, higher escalated arms and phase 3 selection of 0.5/1 mg. Low-arm body tables were inaccessible in our public route; we did not promote provider snippets to a full-body audit or a 24-68-week result.", "original_source": "https://pubmed.ncbi.nlm.nih.gov/26358288/", "source_examination_receipts": [ "deliverables\\hsef_v53_traffic_ranks_06_10_2026-10-13\\glp 1-microdosing\\examinations\\original-21-29-10000.json" ], "body_receipts": [] }, { "pmid": "30122305", "doi": "10.1016/S0140-6736(18)31773-2", "source_type": "primary study report", "study_group": "PMID30122305", "access_depth": "abstract_metadata", "consensus_aspect": "Daily low milligrams cannot be converted to weekly equivalence", "result_comparison": "Consensus labels the obesity dose-ranging original as a daily schedule. The examined Methods-containing abstract explicitly says every active dose was once daily. Its 52-week positive weight results therefore do not establish sub-0.5 mg once-weekly maintenance, and no arithmetic dose conversion was used.", "original_source": "https://pubmed.ncbi.nlm.nih.gov/30122305/", "source_examination_receipts": [ "deliverables\\hsef_v53_traffic_ranks_06_10_2026-10-13\\glp 1-microdosing\\examinations\\original-0-8-10000.json" ], "body_receipts": [] }, { "pmid": "38826889", "doi": "10.7759/cureus.59558", "source_type": "primary study report", "study_group": "PMID38826889", "access_depth": "abstract_metadata", "consensus_aspect": "Lower-than-obesity-dose is not the registered microdose", "result_comparison": "Consensus notes this chart review maintained 1 mg or 2 mg. The examined original confirms six-month maintenance in 16 and nine cases respectively, with only 25 completers from 40 patients. Observed losses at these doses and selected completion do not establish the strict microdose or randomized equivalence.", "original_source": "https://pubmed.ncbi.nlm.nih.gov/38826889/", "source_examination_receipts": [ "deliverables\\hsef_v53_traffic_ranks_06_10_2026-10-13\\glp 1-microdosing\\examinations\\original-8-16-10000.json" ], "body_receipts": [] }, { "pmid": "41421448", "doi": "10.1016/j.clnesp.2025.102885", "source_type": "primary study report", "study_group": "PMID41421448", "access_depth": "abstract_metadata", "consensus_aspect": "Mixed-dose PCOS combination and horizon", "result_comparison": "Consensus describes a six-month 0.25-0.5 mg plus-metformin pilot with fat loss and no lean-mass loss. The original reports the weight contrast after five months, combines metformin with pooled semaglutide doses and finds a nonsignificant lean-mass contrast. We retain these distinctions: no isolated below-0.5 mg causal estimate, no registered 24-week weight endpoint and no positive muscle-function protection result.", "original_source": "https://pubmed.ncbi.nlm.nih.gov/41421448/", "source_examination_receipts": [ "deliverables\\hsef_v53_traffic_ranks_06_10_2026-10-13\\glp 1-microdosing\\examinations\\original-53-60-10000.json" ], "body_receipts": [] }, { "pmid": "42217114", "doi": "10.1007/s12325-026-03636-x", "source_type": "primary study report", "study_group": "PMID42217114", "access_depth": "full_text_partial", "consensus_aspect": "Food-noise recall survey versus necessary mediation", "result_comparison": "Consensus characterizes INFORM as retrospective and recall-based. Our selected original Methods and Results independently confirm self-report, no statistical testing, 550 survey participants but 547 complete FNQ responses, and 39% currently using 2.4 mg. The lower recollected-to-current scores do not establish necessary mediation or low-dose efficacy.", "original_source": "https://pubmed.ncbi.nlm.nih.gov/42217114/", "source_examination_receipts": [ "deliverables\\hsef_v53_traffic_ranks_06_10_2026-10-13\\glp 1-microdosing\\examinations\\original-16-22-10000.json" ], "body_receipts": [ "deliverables\\hsef_v53_traffic_ranks_06_10_2026-10-13\\glp 1-microdosing\\body-presentation-receipts\\42217114-s2-p1-3-4-5-11-13.json", "deliverables\\hsef_v53_traffic_ranks_06_10_2026-10-13\\glp 1-microdosing\\body-presentation-receipts\\42217114-s3-p0-1-4.json" ] }, { "pmid": "41068996", "doi": "10.1111/dom.70141", "source_type": "primary study report", "study_group": "PMID41068996", "access_depth": "abstract_metadata", "consensus_aspect": "Lean mass and grip strength are different outcomes", "result_comparison": "Consensus distinguishes SEMALEAN from older-adult retrospective decline. The original SEMALEAN abstract reports 106 completers, initial 3 kg lean-mass loss followed by stabilization and a 4.5 kg grip increase at 12 months during 2.4 mg treatment. Its uncontrolled design supports the distinction between mass and function, not microdose muscle protection.", "original_source": "https://pubmed.ncbi.nlm.nih.gov/41068996/", "source_examination_receipts": [ "deliverables\\hsef_v53_traffic_ranks_06_10_2026-10-13\\glp 1-microdosing\\examinations\\original-45-53-10000.json" ], "body_receipts": [] }, { "pmid": "40631351", "doi": "10.2147/DDDT.S531778", "source_type": "primary study report", "study_group": "PMID40631351", "access_depth": "abstract_metadata", "consensus_aspect": "Conflicting older-diabetes function evidence", "result_comparison": "Consensus identifies the older-adult retrospective cohort as a contrary functional boundary. The original abstract associates exposure with mass and function decline over 24 months but does not establish random allocation or remove nutrition/comorbidity confounding. Neither this finding nor SEMALEAN proves all doses harmful or protective.", "original_source": "https://pubmed.ncbi.nlm.nih.gov/40631351/", "source_examination_receipts": [ "deliverables\\hsef_v53_traffic_ranks_06_10_2026-10-13\\glp 1-microdosing\\examinations\\original-45-53-10000.json" ], "body_receipts": [] }, { "pmid": "41725422", "doi": "10.1111/dom.70538", "source_type": "primary study report", "study_group": "PMID41725422", "access_depth": "full_text_partial", "consensus_aspect": "Supplemental original-body correction beyond provider coverage", "result_comparison": "FLEX-SEMA was not a cited anchor in the observed Consensus report; our separate original-source retrieval filled this gap. Selected Results show that 5.4% remained on 0.25 mg at three months, while six-month dose maintenance was driven mainly by satisfactory prior results. Body cumulative responder thresholds are 84.4%, 64.6%, 35.4% and 9.4%; the indexed abstract instead mislabels nonoverlapping bin percentages as cumulative. We use the body distinction and do not interpret a final-dose null as noninferiority.", "original_source": "https://pubmed.ncbi.nlm.nih.gov/41725422/", "source_examination_receipts": [ "deliverables\\hsef_v53_traffic_ranks_06_10_2026-10-13\\glp 1-microdosing\\examinations\\original-0-8-10000.json" ], "body_receipts": [ "deliverables\\hsef_v53_traffic_ranks_06_10_2026-10-13\\glp 1-microdosing\\body-presentation-receipts\\41725422-s1-p0-1-7-8.json", "deliverables\\hsef_v53_traffic_ranks_06_10_2026-10-13\\glp 1-microdosing\\body-presentation-receipts\\41725422-s2-p1-3-14-15-16-19.json" ] }, { "pmid": "42323166", "doi": "10.1016/j.ajcnut.2026.101403", "source_type": "primary study report", "study_group": "NCT05548647", "access_depth": "full_text_partial", "consensus_aspect": "Additional long-term objective-subjective dissociation", "result_comparison": "The observed Consensus report explains the need to separate appetite from food noise but does not cite this 60-week original as an anchor. Our selected Methods/Results add the explicit finding: intake and weight differences persist at weeks 40/60 while hunger and food-preoccupation contrasts no longer reach significance. These were VAS/eating-control measures, not a direct intervention on FNQ necessity.", "original_source": "https://pubmed.ncbi.nlm.nih.gov/42323166/", "source_examination_receipts": [ "deliverables\\hsef_v53_traffic_ranks_06_10_2026-10-13\\glp 1-microdosing\\examinations\\original-0-8-10000.json" ], "body_receipts": [ "deliverables\\hsef_v53_traffic_ranks_06_10_2026-10-13\\glp 1-microdosing\\body-presentation-receipts\\42323166-s1-p0-1-3-4-8-12.json", "deliverables\\hsef_v53_traffic_ranks_06_10_2026-10-13\\glp 1-microdosing\\body-presentation-receipts\\42323166-s2-p8-10-19-21-22.json" ] } ], "grade_changed": false, "grade_change_note": "Source-based adjudication; no independent blinded regrade claimed.", "raw_receipts": [ { "path": "deliverables/hsef_v53_traffic_ranks_06_10_2026-10-13/glp1-microdosing/consensus-provider-checkpoint-1551-private.json", "sha256": "402867bbf545618b0aecfd197a70c62fa8e5bbee6ceb136d31064c52c32f9d7f" } ], "independent_blinded_audit": false, "cutoff": "2026-10-13", "completed_utc": "2026-10-13T16:38:31.999413+00:00", "conclusion": "Endpoint hierarchy, experimental scope and original-source limits determine the evidence cards; provider wording does not override them." } }